WO2000008043A9 - Prevention et traitement de pathologie virale - Google Patents

Prevention et traitement de pathologie virale

Info

Publication number
WO2000008043A9
WO2000008043A9 PCT/US1999/017487 US9917487W WO0008043A9 WO 2000008043 A9 WO2000008043 A9 WO 2000008043A9 US 9917487 W US9917487 W US 9917487W WO 0008043 A9 WO0008043 A9 WO 0008043A9
Authority
WO
WIPO (PCT)
Prior art keywords
virus
cell
envelope protein
molecular structure
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/017487
Other languages
English (en)
Other versions
WO2000008043A3 (fr
WO2000008043A2 (fr
Inventor
Jack H Nunberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Montana – Missoula
Original Assignee
University of Montana – Missoula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU57715/99A priority Critical patent/AU5771599A/en
Priority to KR1020017001483A priority patent/KR20010085326A/ko
Priority to IL14121199A priority patent/IL141211A0/xx
Priority to EP99945011A priority patent/EP1102788A4/fr
Priority to CA002338983A priority patent/CA2338983A1/fr
Priority to JP2000563676A priority patent/JP2002522448A/ja
Application filed by University of Montana – Missoula filed Critical University of Montana – Missoula
Priority to BR9912732-6A priority patent/BR9912732A/pt
Publication of WO2000008043A2 publication Critical patent/WO2000008043A2/fr
Publication of WO2000008043A3 publication Critical patent/WO2000008043A3/fr
Anticipated expiration legal-status Critical
Publication of WO2000008043A9 publication Critical patent/WO2000008043A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the inventions consisting of monoclonal antibodies to the FRMS and affinity tagged viral envelope protein, respectively, were made with government support under grant numbers R01 AI44669-01 and R21 AI44312-02 awarded by the National Institutes of Health. The Government has certain rights in these inventions.
  • the present invention relates to the surprising discovery that highly effective vaccines may be constructed which present transitional fusion-related determinants to the immune system that engender unique antibodies capable of potently neutralizing a broad range of primary isolates, from worldwide locations and from different phylogenetic viral clades.
  • the invention relates to the generation of Fusion-Related Molecular Structures (FRMS) which comprise one or more fusion-related determinants.
  • FRMS Fusion-Related Molecular Structures
  • the invention further relates to the discovery that the broad and uniform neutralization of diverse primary isolates indicates that the critical determinants presented by FRMS is highly conserved and may be intimately tied to the basic functioning of the envelope protein in binding and fusion.
  • the present invention provides methods for formation, isolation and purification of the FRMS as well as the use of such FRMS in a variety of compositions and methods, including, for example, as vaccine immunogens, diagnostics, and therapeutics.
  • the present invention concerns FRMS capable of eliciting neutralizing antibodies to viral pathogens and primary isolates of a virus. Antibodies raised to the FRMS can be used to study the molecular pathway toward fusion of the virus and host cell and to identify points of a possible antibody-mediated blockade to that pathway.
  • the invention also relates to the use of antibodies of the invention for anti- viral agents, blood product additives, contraceptive additives passive immunization in post-exposure treatments or fetus immunization.
  • Viruses are infectious agents responsible for many diseases in humans, animals, bacteria and plants, and are therefore of great medical, and commercial importance.
  • a free virus particle called a virion
  • a virion is made up of a genome (which can be RNA or DNA), associated proteins or polyamides, and a protein coat called a capsid.
  • a capsid Some virions are further surrounded by a membranous envelope. Capsid and envelope structures serve to protect the genome from nucleases present in the environment and also serve to facilitate viral attachment and entry into the cell in which it will infect and replicate.
  • a virus must utilize the biosynthetic machinery of the host cell to replicate. Viruses use the synthetic pathways and substrates available in animal cells to maintain and propagate their own genetic information. To gain access to the cell's biomacbinery, the virus must enter or infect the cell. Entrance is facilitated by the presence of one or more viral receptor proteins on host cell membranes. Viral proteins bind to these receptors initiating a complex series of events by which the viral nucleic acid or nucleoproteins are released into the cell.
  • enveloped viruses infection is facilitated by fusion of the viral envelope with a cellular membrane such as a cell surface membrane or an internal membrane.
  • a cellular membrane such as a cell surface membrane or an internal membrane.
  • enveloped viruses are implicated in human and animal disease.
  • HIV human immunodeficiency virus
  • AIDS acquired immune deficiency syndrome
  • HJV replication occurs prominently in CD4 + T lymphocyte populations, and HIV infection leads to depletion of this cell type and eventually to immune incompetence, opportunistic infections, neurological dysfunctions, neoplastic growth, and ultimately death.
  • HIV is a member of the class of lentivirus in the family of retroviruses
  • Retroviruses are small enveloped viruses that contain a single-stranded RNA genome, and replicate via a DNA intermediate produced by a virally-encoded reverse transcriptase, an RNA-dependent DNA polymerase (Varnius, H., 1988, Science 240:1427-1439).
  • the HIV viral particle comprises a viral core, composed in part of capsid proteins, together with the viral RNA genome and those enzymes required for early
  • Myristylated gag protein forms an outer shell around the viral core, which, in turn, is surrounded by a lipid membrane envelope derived from an infected cell membrane.
  • the HIV envelope surface glycoproteins are synthesized as a single 160 kilodalton precursor protein which is cleaved by a cellular protease during viral budding into two glycoproteins, gp41 and gpl20.
  • gp41 is a transmembrane glycoprotein and gpl20
  • CD4 cellular membrane protein acts as a cellular receptor for the HIV-1 virus (Dalgleish, A., et al., 1984, Nature
  • the viral envelope protein Upon interaction of the viral envelope protein and cellular receptor, the
  • envelope protein-CD4 complex undergoes conformational changes facilitating subsequent interaction with host cellular co-receptors to form a trimolecular complex. Further conformational changes in the trimolecular complex allow fusion of the apposed cell membrane and virus envelope releasing viral genetic material into the cell.
  • cytotoxic therapy may also lead to suppression of CD8 + T cells, which are essential to the control of HIV, via killer cell activity (Blazevic, V., et al, 1995, AIDS Res. Hum. Retroviruses 11:1335-1342) and by the release of suppressive factors, notably the chemokines Rantes, MlP-l ⁇ and MlP-l ⁇ (Cocchi, F., et al., 1995, Science 270:1811-1815).
  • suppressive factors notably the chemokines Rantes, MlP-l ⁇ and MlP-l ⁇
  • Another major concern in long-term chemical anti-retro viral therapy is the development of HIV mutations with partial or complete resistance (Lange, J.M., 1995, AIDS Res.
  • CD4 the cell surface receptor for HIV.
  • Recombinant soluble CD4 has been shown to inhibit infection of CD4 + T cells by some HIV-1 strains (Smith, D.H., et al., 1987, Science 238 : 1704- 1707).
  • Certain primary HTV- 1 isolates are relatively less sensitive to inhibition by recombinant CD4 (Daar, E., et al., 1990, Proc. Natl. Acad. Sci. USA 87:6574- 6579).
  • Late stage processing is dependent on the activity of a viral protease, and drugs are being developed which inhibit this protease (Erickson, J., 1990, Science 249:527- 533).
  • drugs are being developed which inhibit this protease (Erickson, J., 1990, Science 249:527- 533).
  • chemokines produced by CD8 + T cells have been implicated in suppression of HIV infection (Paul, W.E., 1994, Cell 82:177; Bolognesi, D.P., 1993, Semin. Immunol. 5:203).
  • chemokines RANTES, MJJP-l ⁇ and MlP-l ⁇ which are secreted by CD8 + T cells, were shown to suppress HIV-1 p24 antigen production in cells infected with HIV-1 or fflV-2 isolates in vitro (Cocchi, F, et al., 1995, Science 270:1811-1815). Thus, these and other chemokines may prove useful in therapies for HIV infection. The clinical outcome, however, of all these and other candidate drugs is still in question.
  • VACCINES Another important strategy in anti- viral treatment and prevention is the development of vaccines. Due to the potential pandemic nature of viral infection, such as HIV, there is a significant need for effective vaccines.
  • inactivated or attenuated pathogens Traditional methods for preparing vaccines include the use of inactivated or attenuated pathogens.
  • a suitable inactivation of the pathogenic microorganism renders it harmless as a biological agent but does not destroy its immunogenicity. Injection of these "killed" particles into a host will then elicit an immune response capable of preventing a future infection with a live microorganism.
  • a major concern in the use of killed vaccines (using inactivated pathogen) is failure to inactivate all the microorganism particles. Even when this is accomplished, since killed pathogens do not multiply in their host, or for other unknown reasons, the immunity achieved is often incomplete, short lived and requires multiple immunizations. Finally, the inactivation process may alter the microorganism's antigens, rendering them less effective as immunogens.
  • Attenuation refers to the production of strains of pathogenic microorganisms which have essentially lost their disease-producing ability.
  • One way to accomplish this is to subject the microorganism to unusual growth conditions and/or frequent passage in cell culture. Mutants are then selected which have lost virulence but yet are capable of eliciting an immune response. Attenuated pathogens often make good immunogens as they actually replicate in the host cell and elicit long lasting immunity.
  • live vaccines the most worrisome being insufficient attenuation and the risk of reversion to virulence.
  • SUBSTITUTE SHEET (RULE 28) the most common candidates to act as immunogens for anti-HTV vaccine development.
  • Several groups have begun to use various portions of gpl60, gpl20, and/or gp41 as immunogenic targets for the host immune system. See for example, Ivanoff, L., et al., U.S. Pat. No. 5,141,867; Saith, G., et al., WO92/22,654; Shafferman, A., WO91/09,872;
  • Isolate viruses were largely refractory to neutralization by rgpl20 vaccine sera (Cohen, J., 1993, Science 262:980; Cohen, J., 1994, Science 264:1839).
  • PB Is peripheral blood lymphocytes
  • Laboratory adapted strains are those which are persistently grown in established T cell lines in the laboratory (See Wrin et al., 1995, J. of Virology 69:39). Previous vaccine candidates have elicited neutralizing antibodies to laboratory-adapted strains. For example, Wrin et al.,
  • Neutralizing antibodies are important to prevent binding and fusion of the virus to the host cell.
  • the action of antibodies that neutralize laboratory-adapted isolates have been analyzed.
  • Neutralizing antibodies directed specifically to the CD4 binding domain on gpl20 interfere with CD4 binding.
  • some neutralizing antibodies inhibit interaction with the co-receptor (Trkola et al., 1998, Journal of Virology 72:1876; Wu, et al, 1996, Nature 384:179-83).
  • the present invention is based on the surprising discovery that highly effective vaccines may be constructed which present transitional fusion-related determinants to the immune system that engender unique antibodies capable of potently neutralizing a broad range of primary isolates of enveloped viruses, from worldwide locations and from different phylogenetic viral clades.
  • the vaccine of the invention comprise as immunogens Fusion-Related Molecular Structures (FRMS) which comprise one or more fusion-related determinants.
  • FRMS Fusion-Related Molecular Structures
  • the invention is further based on the discovery that the broad and uniform neutralization of diverse primary isolates indicates that the critical determinants presented by FRMS are highly conserved and may be intimately tied to the basic functioning of the envelope protein in binding and fusion.
  • the present invention provides the use of such FRMS in a variety of compositions and methods, including, for example, as vaccine immunogens, blood product additives, anti-viral agents, diagnostics and therapeutics.
  • the present invention concerns FRMS capable of eliciting neutralizing antibodies to enveloped viral pathogens. Epitopes which elicit these neutralizing antibody result from conformational changes during the process of binding and fusion of the viral envelope and host cell membranes.
  • the complexes result from the interaction of viral proteins with at least one host cellular receptor or co-receptor and are created by co-culturing cells transformed with a nucleic acid expressing a viral protein and cells expressing host cellular receptor(s).
  • the cells recombinantly express the host cell receptor(s).
  • cultures are fixed at the onset of cell-cell interaction to preserve fusion-competent immunogens.
  • the fusion-related immunogens are formed as a result of the interaction of the major human immunodeficiency virus type 1 (HIV-1) envelope protein, the host cellular receptor CD4 and the host cellular co-receptor CCR5.
  • HIV-1 major human immunodeficiency virus type 1
  • Vaccinating with the FRMS of the subject invention as immunogens raises an immune response to the viral pathogen and elicits the production of neutralizing antibodies in the vaccinated host.
  • antibodies raised to the FRMS can be used to study the molecular pathway toward fusion of the virus and host cell and to identify points of a possible antibody-mediated blockade to that pathway.
  • specific high-affinity "tags" may be expressed as part of the envelope protein or host cellular receptor(s) that faclilitates isolation and purification of the FRMS of the invention.
  • the present invention further relates to the development of monoclonal antibodies (mAb) elicited by these FRMS immunogens.
  • Monoclonal antibodies which are capable of neutralization of primary isolates are provided.
  • Neutralizing mAbs to functionally conserved fusion-dependent epitopes may also be useful for passive immunization in post-exposure treatments or fetus immunization.
  • the present invention provides an isolated molecular structure comprising an epitope formed as a result of association of (a) an envelope protein of an enveloped virus, with (b) one or more cellular membrane proteins, which envelope protein and cellular membrane proteins are necessary and sufficient under suitable conditions for fusion of said envelope of the virus with a cell membrane containing said cellular membrane proteins.
  • the present invention provides an isolated molecular structure comprising an epitope formed as a result of association of (a) an HIV envelope protein, or a mutant thereof that assembles into the viral envelope; with (b) human CD4 and a co-receptor for HIV fusion.
  • co-receptor is the chemokine receptor CCR5 or CXCR4.
  • the molecular structure is formed by association of a mutant of HIV gp41 that is fusion-defective.
  • the mutant contains one or more mutations selected from the group consisting of V2E, G10V, V570R, and Y586E.
  • the molecular structure is formed by association of wild-type HTV envelope protein.
  • the present invention provides an isolated molecular structure comprising an epitope formed as a result of association of (a) a mutant envelope protein of an enveloped virus, which envelope protein in wild-type form functions in fusion of the viral envelope with a host cell membrane, and which mutant envelope protein is fusion-defective; and (b) one or more host cellular membrane proteins which function as receptors for said envelope protein.
  • said virus is from a viral family is selected from the group consisting of Retro viridae, Rhabdoviridae, Caronaviridae, Filoviridae, Poxviridae, Bunyaviridae, Flaviviridae, Togaviridae, Orthomyxoviridae, Paramyxoviridae, and Herpesviridae.
  • the envelope protein is El and E2 of HCV and the cellular membrane protein is CD81.
  • the molecular structure is a cross-linked cellular molecular structure.
  • the molecular structure is isolated from a cell lysate.
  • the cellular molecular structure comprises cells recombinantly expressing the envelope protein.
  • the cell lysate is from a plurality of cells comprising cells recombinantly expressing the envelope protein.
  • the cellular molecular structure further comprises cells recombinantly expressing the one or more host cellular membrane proteins.
  • the present invention provides a recombinant enveloped virus, wherein said virus recombinantly expresses on its envelope a cell receptor for a native envelope protein of said virus.
  • said cell receptor is human CD4 or a co-receptor for HIV, or said virus recombinantly expresses both human CD4 and said co-receptor.
  • said suitable conditions comprise a lowering of pH.
  • the cross-linked cellular molecular structure further comprises a cross-linked viral particle of said virus, containing said envelope protein.
  • the present invention provides a vaccine formulation comprising an immunogenic amount of the molecular structure and a pharmaceutically acceptable carrier.
  • the present invention provides a monoclonal antibody to the molecular structure.
  • the antibody is labeled.
  • the present invention provides a purified polyclonal antiserum specific to the molecular structure.
  • the present invention provides a contraceptive jelly, foam, cream, or ointment comprising an amount of the antibody effective to inhibit or decrease infection by the virus.
  • the present invention provides a contraceptive jelly, foam, cream, or ointment comprising an amount of the antibody effective to inhibit or decrease infection by HTV.
  • the present invention provides a contraceptive jelly, foam, cream, or ointment comprising an amount of the antiserum effective to inhibit or decrease infection by HTV.
  • the present invention provides a sample of mammalian blood, to which an amount of the antibody has been added effective to inhibit or decrease infection by the virus.
  • the present invention provides a sample of human blood, to which an amount of the antibody has been added effective to inhibit or decrease infection by HIV.
  • said envelope protein or host cellular membrane proteins further comprises an affinity tag.
  • said envelope protein, CD4, or co- receptor further comprises an affinity tag.
  • the antibody is labeled.
  • the present invention provides a kit comprising in one or more containers a labeled monoclonal antibody to the molecular structure.
  • the present invention provides a kit comprising in one or more containers a labeled monoclonal antibody to the molecular structure.
  • the kit comprises the molecular structure in a separate container.
  • the present invention provides a cell line that recombinantly expresses an envelope protein of an enveloped virus that functions in fusion of the viral envelope with a host cell membrane, or a mutant form of said envelope protein that is fusion-defective, which cell line expresses one or more cellular membrane proteins that function as receptors for said envelope protein.
  • said one or more proteins that function as receptors are recombinantly expressed.
  • the present invention provides a cell line that recombinantly expresses HIV g l 60, which cell line expresses CD4 and a co-receptor for HIV; said cell line lacking a functional protease that cleaves gpl 60 to produce gpl20 and gp41.
  • the present invention provides a method of treating or preventing infection by a virus in a subject comprising administering to the subject an immunogenic amount of the molecular structure effective to treat or prevent infection by the virus.
  • the subject is a human. In another embodiment, the subject is a domestic animal.
  • the present invention provides a method of treating or preventing infection by HIV in a human comprising admimstering to the human an immunogenic amount of the molecular structure effective to treat or prevent infection by HTV.
  • the present invention provides a method of treating or preventing infection by a virus in a subject comprising administering to the subject an amount of the monoclonal antibody effective to treat or prevent infection by the virus.
  • the present invention provides a method of treating or preventing infection by HTV in a human comprising administering to the human an amount of the monoclonal antibody effective to treat or prevent infection by HTV.
  • said human has a high risk of HIV infection.
  • the method is for treatment of AIDS in said human.
  • the present invention provides a method for treating or preventing infection by HTV in a human fetus comprising administering to a pregnant human containing said fetus an amount of the monoclonal antibody effective to treat or prevent infection by HIV in said fetus.
  • the present invention provides a method of inhibiting infection by a virus in a sample of blood comprising contacting said sample of blood with an amount of the monoclonal antibody effective to inhibit infection by said virus.
  • the present invention provides a method of inhibiting infection by HIV in a sample of human blood comprising contacting said sample of human blood with an amount of the monoclonal antibody effective to inhibit infection by HIV.
  • the present invention provides a method of decontaminating surgical or dental tools comprising contacting said tools with an amount of the monoclonal antibody effective to inhibit infection by said virus.
  • the present invention provides a method of decontaminating surgical or dental tools comprising contacting said tools with an amount of the monoclonal antibody effective to inhibit infection by HTV.
  • the present invention provides a method for monitoring the production of antibody to the molecular structure in a subject previously administered an amount of the molecular structure comprising isolating from said subject a sample comprising serum; and detecting the presence of any antibodies to the molecular structure in said serum.
  • said detecting is carried out by a method comprising performing a competitive immunoassay with labeled antibody to the molecular structure.
  • the present invention provides a method of producing an immunogen for use in a vaccine for the treatment or prevention of infection by a virus comprising the following steps in the order stated: (a) contacting an envelope protein or chimeric form thereof of an enveloped virus, which envelope protein functions in fusion of the viral envelope with a cell membrane, or a mutant form or chimeric form thereof of said envelope protein that is fusion-defective, with one or more cell proteins or chimeric forms thereof that function as receptors for said envelope protein; (b) exposing said envelope protein or chimeric form thereof or mutant form or chimeric form thereof, and said one or more host cell proteins or chimeric forms thereof, to a cross-linking agent; and (c) isolating a cross-linked structure comprising said envelope protein or chimeric form thereof or mutant form or chimeric form thereof.
  • the present invention provides a method of producing an immunogen for use in a vaccine for the treatment or prevention of infection by HIV comprising the following steps in the order stated: (a) co-culturing a first cell recombinantly expressing HTV envelope protein or a chimeric form thereof, or a mutant form or chimeric form thereof of said envelope protein that is fusion-defective, with a second cell that expresses (i) human CD4 or a chimeric form thereof, and (ii) a co-receptor for HIV or a chimeric form thereof; (b) exposing said envelope protein or chimeric form thereof or mutant form or chimeric form thereof, and said CD4 or chimeric form thereof and co-receptor or chimeric form thereof, to a cross-linking agent; and (c) isolating a cross-linked structure comprising said envelope protein or chimeric form thereof or mutant form or chimeric form thereof.
  • said virus is HIV and said host cell proteins are human CD4 and a co-receptor for HIV.
  • said second cell recombinantly expresses CD4 or said co- receptor or both CD4 and said co-receptor or chimeric forms of any of the foregoing.
  • said first and second cell are the same cell type.
  • said envelope protein or chimeric form thereof or mutant form or chimeric form thereof is present on a viral particle or virus-like particle.
  • said cross-linked structure is a cross-linked cellular complex.
  • the virus is selected from the group consisting of
  • Retroviridae Rhabdoviridae, Coronaviridae, Filoviridae, Poxviridae, Bunyaviridae, Flaviviridae, Togaviridae, Orthomyxoviridae, Paramyxoviridae, and Herpesviridae.
  • said contacting step occurs by infecting cells expressing said host cell proteins with said virus expressing said envelope protein or chimeric form thereof or mutant form or chimeric form thereof.
  • a chimeric form of said envelope protein or one of said host cell proteins is contacted, said chimeric form comprising an affinity tag.
  • a chimeric form of said envelope protein or CD4 or said co-receptor is contacted, said chimeric form comprising an affinity tag.
  • the present invention provides a method of producing an immunogen for use in a vaccine for the treatment or prevention of infection by HTV comprising the following steps in the order stated: (a) co-culturing a first cell recombinantly expressing HIV envelope protein or a chimeric form thereof, or a mutant form or chimeric form thereof of said envelope protein that is fusion-defective, with a second cell that expresses (i) human CD4 or a chimeric form thereof, and (ii) a co-receptor for HTV or a chimeric form thereof wherein at least one of said chimeric forms comprising an affinity tag is expressed; (b) lysing said co-cultured cells to form a cell lysate under non-denaturing conditions; and (c)
  • SUBSTITUTE SHEET (RULE 28) isolating from said cell lysate a molecular structure comprising said envelope protein or chimeric form thereof or mutant form or chimeric form thereof by a method comprising contacting said cell lysate with a binding partner to said affinity tag and recovering a molecular structure bound to said affinity tag.
  • the present invention provides a cross-linked structure that is the product of the method.
  • the present invention provides a monoclonal antibody to the structure of that neutralizes in vitro the following primary isolates of HIV: 92US657, 92US660, 92RW023,
  • the present invention provides a contraceptive, jelly, foam, cream or ointment comprising an amount of the antibody to inhibit or decrease infection by HJV.
  • the present invention provides a method of treating or preventing infection by a virus in a subject comprising administering to the subject an immunogenic amount of the structure effective to treat or prevent infection by the virus.
  • the present invention provides a method of treating or preventing infection by HIV in a human comprising administering to the human an immunogenic amount of the molecular structure effective to treat or prevent infection by HIV.
  • the present invention provides a method of decontaminating surgical or dental tools comprising contacting said tools with an amount of the monoclonal antibody effective to inhibit infection by HIV.
  • the present invention provides a method of decontaminating surgical or dental tools comprising contacting said tools with an amount of the monoclonal antibody effective to inhibit infection by said virus.
  • the present invention provides a method of screening a molecular structure for vaccine efficacy comprising immunizing a transgenic non-human mammal with the molecular structure, wherein said transgenic non-human mammal expresses from one or more transgenes both human CD4 and a co-receptor for HIV, and detecting any neutralizing antibodies to HIV that are produced by said mammal.
  • the present invention provides a method of screening a molecular structure for vaccine efficacy comprising immunizing a transgenic non-human mammal with the molecular structure, wherein said transgenic non-human mammal expresses from one or more transgenes said one or more host cellular membrane proteins; and detecting any neutralizing antibodies to said virus that are produced by said mammal.
  • the mammal is a mouse.
  • said first cell recombinantly expresses HTV envelope protein or a chimeric form thereof. 4.
  • BRIEF DESCRIPTION OF THE FIGURES Figure 1. Neutralization of the homologous 168P PI virus by FC and FI vaccine sera.
  • mice hu CD4+, hu CCR5+, mouse CD4+
  • Sera were tested for neutralization of 168P using U87-CD4 cells expressing either CXCR4 (black symbols) or CCR5 (white symbols).
  • Data represent averages of three to six neutralization assays using serum obtained 2 weeks following second and third immunization.
  • FIG. 2A-B Neutralization of P168 by FC but not FI, vaccine sera.
  • HIV p24 antigen was determined after 5 days of culture by ELISA (Coulter Corporation) and values were normalized to the virus control (36 ng/ml). Asterisks indicates p24 antigen levels below the limit of detection at the dilution used in the ELISA.
  • FC vaccine serum does not neutralize pseudotyped HIV virions bearing amphotropic MLV envelope protein (A) or primary SIVmac251 (B).
  • Amphotropic MLV envelope protein ampho MLV pseudotype
  • FI antisera For HIV bearing an amphotropic MLV envelope protein (ampho MLV pseudotype) neutralization sensitivity with pooled FC and FI antisera was determined in U87-CD4-CXCR4 cells.
  • SIVmac251 neutralization was determined in U87-CD4-CCR5 cells. Symbols are: FC Immunogen (black squares) and FI immunogen (Cos-env + U87 cells, gray circles).
  • FIG. 4A-B Neutralization of TCLA 168C virus by FI vaccine sera.
  • Neutralization sensitivity of the 168P PI virus (A) and its TCLA derivative 168C (B) were tested in U87- CD4-CXCR4 cells with pooled sera: FC immunogen (black squares), FI immunogens (COS-env + U87 cells, gray circles; COS-env + U87-CD4 cells, gray diamonds; COS-env +sCD4, white diamonds), and mock-transfected cell controls (white circles).
  • FIG. 7 PI virus neutralization activity is not adsorbed by intact U87-CD4-CCR5 cells.
  • Pooled FC vaccine serum was incubated with U87-CD4 CCR5 cells (while squares) or in an empty microculture well (mock, black squares).
  • Pooled FI serum (COS-env + U98-CD4) was similarly treated (white and black circles, respectively). Sera were tested for remaining neutralization of 168P with U87-CD4-CCR5 cells.
  • FIG. 1 Neutralizing activity of two HIV Clade B primary isolates with hybridoma supernatants.
  • FIG. 9 Serum titers of mice immunized with fusion-competent vaccine immunogens.
  • White square represents fusion-competent (FRMS) immunogen (env+with CD4/CCR5); black circles represent immunogen from cells expressing envelope protein immunogen and cells expressing neither CD4 nor CCR5 (env); white circles represent immunogen from cells expressing envelope protein and cells expressing CD4 immunogen (env+CD4); white triangle represent cell controls expressing CD4 and CCR5 immunogen (CD4/CCR5).
  • FRMS fusion-competent
  • FRMS fusion-competent
  • black circles represent immunogen from cells expressing envelope protein immunogen and cells expressing neither CD4 nor CCR5 (env)
  • white circles represent immunogen from cells expressing envelope protein and cells expressing CD4 immunogen (env+CD4)
  • white triangle represent cell controls expressing CD4 and CCR5 immunogen (CD4/CCR5).
  • SUBSTITUTE SHEET (RULE 2&) invention.
  • Black circles represent fusion-competent (FRMS) immunogen (env with CD4/CCR5); white squares represent immunogen from cells expressing envelope protein (env); white circles represent immunogen from cells expressing envelope protein and CD4 (env + CD4).
  • Envelope protein co-purified with CD4-Spep and CCR5-Spep detected by Western blot analysis, a) 168P envelope protein isolated following co-culture with cells expressing CD4-Spep b) 168P envelope protein isolated following co-culture with cells expressing CD4 and CCR5-Spep c) 168P envelope protein was undetectable following co-culture with mock-transfected cells.
  • the present invention concerns fusion-related molecular-structures (FRMS) capable of eliciting neutralizing antibodies to enveloped viral pathogens.
  • the FRMS of the invention comprise epitopes formed as a result of the association of one or more cellular molecules with one or more viral envelope molecules.
  • the process of viral envelope fusion with a cell membrane is initiated following binding of a viral envelope protein to specific cell receptors and/or co-receptors on the host cell and involves fusion of the viral envelope with surface or internal cell membranes. Fusion is driven by conformational changes which occur within the envelope-receptor/co-receptor complex. As not intended to be limited by a particular mechanism, it is believed that the conformational changes that occur during fusion reveal new and unique immunogenic epitopes for neutralizing antibodies.
  • the fusion-related molecular structures of the subject invention mimic the conformational intermediates formed during fusion.
  • the FRMS of the invention may be used for a variety of purposes including but not limited to those presented in Sections 5.5 and 5.7, herein.
  • the FRMS when used to vaccinate host animals elicits neutralizing antibodies to the infecting virus, and thus provide novel effective components of vaccine formulations of the invention, for treatment, or prevention of viral infection and its undesirable consequences.
  • the present invention provides an isolated molecular structure comprising an epitope formed as a result of association of (a) an envelope protein of an enveloped virus, with (b) one or more cellular membrane proteins, which envelope protein and cellular membrane proteins are necessary and sufficient under suitable conditions for fusion of said envelope of the virus with a cell membrane containing said cellular membrane proteins.
  • a cellular membrane protein includes proteins of the cell surface membrane and internal membranes (including but not limited to the endoplasmic reticulum membrane).
  • Such cellular membrane protein may be an integral membrane protein (e.g., a trans-membrane protein), or may be attached to the membrane by an attached lipid (e.g., fatty acid chain or prenyl group) or by an oligosaccharide (e.g., to a phopholipid, phosphatidylinositol), or the cellular membrane protein may also be associated with the membrane by non-covalent interactions (e.g., by association with an integral membrane protein).
  • an integral membrane protein e.g., a trans-membrane protein
  • an attached lipid e.g., fatty acid chain or prenyl group
  • an oligosaccharide e.g., to a phopholipid, phosphatidylinositol
  • the cellular membrane protein may also be associated with the membrane by non-covalent interactions (e.g., by association with an integral membrane protein).
  • the present invention also provides an isolated molecular structure comprising an epitope formed as a result of association of (a) a mutant envelope protein of an enveloped virus, which envelope protein in wild-type form functions in fusion of the viral envelope with a host cell membrane, and which mutant envelope protein is fusion- defective; and (b) one or more host cellular membrane proteins which function as receptors for said envelope protein.
  • the present invention provides an isolated molecular structure comprising an epitope formed as a result of association of (a) an HIV envelope protein, or a mutant thereof that assembles into the viral envelope; with (b) human CD4 and a co-receptor for HIV fusion.
  • the co-receptor is the chemokine receptor CCR5 or CXCR4.
  • the molecular structure is formed by association of a mutant of HTV gp41 that is fusion-defective.
  • the mutant contains one or more mutations selected from the group consisting of V2E, G10V, V570R, and Y586E.
  • the molecular structure is formed by association of wild-type HTV envelope protein.
  • the envelope protein is El and E2 of Flavivirus HCV and the cellular membrane protein is CD81.
  • the present invention also provides a method of producing an immunogen for use in a vaccine for the treatment or prevention of infection by a virus comprising the following steps in the order stated: (a) contacting an envelope protein or chimeric form thereof of an enveloped virus, which envelope protein functions in fusion of the viral envelope with a cell membrane, or a mutant form or chimeric form thereof of said envelope protein that is fusion-defective, with one or more cell proteins or chimeric forms thereof that function as receptors for said envelope protein; (b) exposing said envelope protein or chimeric form thereof or mutant form or chimeric form thereof, and said one or more host cell proteins or chimeric forms thereof, to a cross-linking agent; and (c) isolating a cross- linked structure comprising said envelope protein or chimeric form thereof or mutant form or chimeric form thereof.
  • said virus is HIV and said host cell proteins are human CD4 and a co-receptor for HIV.
  • the present invention also provides a method of producing an immunogen for use in a vaccine for the treatment or prevention of infection by HIV comprising the following steps in the order stated: (a) co-culturing a first cell recombinantly expressing HIV envelope protein(s) or a chimeric form thereof, or a mutant form or chimeric form thereof of said envelope protein that is fusion-defective, with a second cell that expresses (i) human CD4 or a chimeric form thereof, and (ii) a co-receptor for HIV or a chimeric form thereof; (b) exposing said envelope protein or chimeric form thereof or mutant form or chimeric form thereof, and said CD4 or chimeric form thereof and co-receptor or chimeric form thereof, to a cross-linking agent; and (c) isolating a cross- linked structure comprising said envelope protein or
  • said second cell recombinantly expresses CD4 or said co-receptor or both CD4 and said co-receptor or chimeric forms of any of the foregoing.
  • the present invention provides a method of producing an immunogen for use in a vaccine for the treatment or prevention of infection by HIV comprising the following steps in the order stated: (a) co-culturing a first cell recombinantly expressing HIV envelope protein or a chimeric form thereof, or a mutant form or chimeric form thereof of said envelope protein that is fusion-defective, with a second cell that expresses (i) human CD4 or a chimeric form thereof, and (ii) a co-receptor for HIV or a chimeric form thereof wherein at least one of said chimeric forms comprising an affinity tag is expressed; (b) lysing said co-cultured cells to form a cell lysate under non- denaturing conditions; and (c) isolating from said cell
  • the present invention relates to FRMS which comprise an epitope formed as a result of the association of one or more viral envelope molecule(s) and one or more host cell molecule(s).
  • the FRMS of the invention encompass structures resulting from the association of at least one viral envelope protein and at least one host cell protein.
  • a FRMS of the invention may encompass fusion-competent complexes (such as complexes formed during fusion events of the viral envelope with a cellular membrane), fusion-defective complexes (such as those formed during pre-fusion events between a fusion-defective viral envelope and a cellular membrane) as well as complexes formed by the association of one or more viral envelope molecules with one or more cellular receptor and/or co-receptor for the virus.
  • the FRMS result from the association of HIV envelope protein with CD4 and a chemokine receptor.
  • the FRMS of the invention thus comprise epitopes capable of eliciting neutralizing antibodies to the virus.
  • the FRMS of the invention are formed by a variety of methods as described herein.
  • cells expressing one or more components whose association results in the FRMS are cultured to form the FRMS. All the components may be expressed on one cell, or a first component may be expressed on one cell, and a second component may be expressed on a different cell, and a third component (if any) may be expressed on one of the foregoing cells or a different cell.
  • one of the cells may be replaced by a viral particle or pseudovirus or recombinant virus or virus-like particle containing the component(s) on its surface.
  • FRMS may be formed by the interaction of endogenous molecules, exogenous molecules (e.g. recombinantly expressed) or any combination thereof.
  • a soluble form of a viral envelope protein of a envelope virus is used in the formation of a FRMS of the invention.
  • the soluble envelope protein may be added t o host cells in vitro which host cells express the receptor(s) for the virus.
  • the association of the soluble viral envelope protein and host cell receptor(s) results in the formation of a FRMS.
  • one or more soluble cell recptor(s) are used in formation of the FRMS.
  • soluble cellular receptor(s) whose association with the viral envelope protein(s) results in the formation of a FRMS, may be used in the formation of a FRMS by contacting the viral envelope protein(s) with said soluble cell receptor(s).
  • all of the components whose association result in the formation of the FRMS are in a soluble form and the FRMS is reconstitutional in vitro.
  • the reconstitution of a FRMS may optionally be aided by the addition of a mAb to the FRMS.
  • the FRMS is forced upon a decrease in pH.
  • pH-medicated cell fusion allows for the formulation of the FRMS for enveloped viruses which cellular membrane proteins are located in internal cellular membranes.
  • the cellular components involved in the formation of a FRMS for a particular virus include the cell receptors and/or co-receptors for the particular virus. In a specific embodiment, at least some of these components are endogenously expressed by the cell. Thus, any cell known in the art which expresses a cellular component of the FRMS may be used in the formation of a FRMS.
  • Cells expressing native cellular receptors and/or co-receptors for viral proteins can be used.
  • human CD4 is known in the art as a cellular receptor for HIV.
  • cells endogenously expressing CD4 are used in the formation of a FRMS.
  • Cells endogenously expressing a component of the complexes of the invention may comprise one or more of the cellular components used to form the FRMS.
  • cells may be used which express all of the required cellular components of the FRMS or cells may be used which do not express all of the required cellular components.
  • any cell which expresses both CD4 and an HIV co-receptor, such as CCR5 may be used in the formation of an HTV FRMS.
  • any cell which endogenously express CD4 but does not endogenously express an HIV co- receptor in this embodiment, and as discussed below, components of the complex which are not endogenously expressed may be introduced into the cell and recombinantly expressed.
  • additional cellular components of the complex are introduced to the cell such that the cell expresses both endogenous and exogenous cellular components.
  • the co-receptor CXCR4 is predominantly located on T cell lines.
  • the co-receptor CCR5 is predominantly located on macrophage cells.
  • the co-receptor CXCR4 is predominantly located on T cell lines.
  • the co-receptor CCR5 is predominantly located on macrophage cells.
  • Exogenous components may be introduced into the cell by any method known in the art, including those described in Section 5.1.2. below.
  • a cell transformed by means of a viral gene or genome integration, which expresses a viral component of the FRMS may be used in the formation of a fusion related complex.
  • the cell may be said to endogenously express a viral component important in the construction of an FRMS.
  • Such virally-transformed cells may also endogenously express one or more cellular components of the FRMS.
  • viral particles may be used as a source of endogenous expression of viral components of a FRMS.
  • any of the components important in the construction of a FRMS or fragments, analogs or derivatives thereof may be introduced into a cell such that the exogenous component is expressed in the cell.
  • the present invention encompasses expression systems, both eucaryotic and procaryotic expression vectors, which may be used to express a component important in the formation of a FRMS or fragment, analog or derivative thereof of the present invention.
  • the viral envelope protein is expressed in a host cell.
  • the exogenous viral envelope protein may be introduced into the cell by transfection or viral vectors as described herein, or by infection with the live or attenuated virus comprising the viral envelope protein.
  • viral infection can lead to production of a viral envelope protein in preferred embodiments, the expression of a viral envelope protein on the cell membrane is enhanced by the modification (e.g.
  • targeting signals are known in the art that enhance delivery of cellular proteins to particular subcellular compartments or locations.
  • an endoplasimic reticulum signal, KDEL, (one letter amino acid codes) could be engineered into the viral envelope protein to promote targetry of the protein to the ER when a cell is infected with the virus.
  • the invention also provides a cell expressing the viral and cellular components important for the formation of a FRMS.
  • a cell is constructed to express the cell receptor and/or co-receptor for a virus and to recombinantly express the viral envelope protein.
  • Such cell may endogenously express the host cell receptors and/or co-receptors for the virus or recombinantly express one or both of such protein(s).
  • the nucleic acids encoding such proteins may be expressed from different vectors or from a single vector (e.g., wherein a vector comprises multiple genes operably linked to a single promoter).
  • a cell is constructed to recombinantly express CD4, a co-receptor CCR5 or CXCR4 and HIV gpl60.
  • gpl20 and gp41 may be used in place of gpl60.
  • the viral envelope protein is also constructed such that it is lacking the native protease site responsible for cleavage ofgpl60 to gpl20 and gp41.
  • an alternative protease site is constructed into the viral envelope protein which protease is not native to the host cell (such as a bacterial protease). Formation of the FRMS is triggered on the cell expressing the three proteins, by contacting the cell with the non- native protease (such as by adding an amount effective to induce cleavage, to the cell media).
  • a variety of proteases and protease sites are known in the art and may be used in accordance with the invention.
  • nucleotide sequence coding for a viral envelope protein or cellular receptor protein of the invention or a functionally active analog or fragment or other derivative thereof can be inserted into an appropriate expression vector, e.g., a vector which contains the necessary elements for the transcription and translation of the inserted protein- coding sequence and/or for carrying out the methods of the invention.
  • the invention encompasses the use of DNA expression vectors and/or viral vectors that contain coding sequences of a component of FRMS or analog, derivative or fragment thereof operatively associated with a regulatory element that directs expression of the coding sequences and genetically engineered host cells that contain any of the foregoing coding sequences operatively associated with a regulatory element that directs the
  • DNA expression vectors and viral vectors containing the nucleic acids encoding a component important in the formation of a FRMS of the present invention may be produced by recombinant DNA technology using techniques well known in the art.
  • nucleic acid containing sequences encoding a component important in the formation of a FRMS or analog, derivative or fragment thereof are described herein.
  • Methods which are well known to those skilled in the art can be used to construct expression vectors containing gene product coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in
  • gene product sequences may be chemically synthesized using, for example, oligonucleotide synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, M.J. ed., URL Press, Oxford, which is incorporated by reference herein in its entirety.
  • Gene expression may be regulated by a variety of methods known in the art including but not limited to those presented in Mizuno, T. et al.,
  • the nucleic acids or DNA encoding one or more components which result in the formation of the FRMS may be introduced into a cell may be accomplished by a variety of methods, such as liposomes, electroporation, transfection, viral vectors, bacteriophage, etc.
  • nucleic acids encoding one or more components important in the formation of a FRMS is accomplished by packaging plasmid DNA comprising the nucleic acids that code for the component(s) into liposomes or by complexing the plasmid DNA comprising nucleic acids that code for the component(s) with lipids or liposomes to form DNA-lipid or DNA-liposome complexes.
  • the liposome is composed of cationic and neutral lipids commonly used to transfect cells in vitro. The cationic lipids complex with the plasmid DNA and form liposomes. Cationic and neutral liposomes are contemplated by this invention.
  • Cationic liposomes can be complexed with the a negatively-charged biologically active molecule (e.g., DNA) by mixing these components and allowing them to charge-associate.
  • Cationic liposomes are particularly useful with a nucleic acid because of the nucleic acids negative charge.
  • Examples of cationic liposomes include lipofectin, lipofectamine, lipofectace and DOTAP (Hawley-Nelson et al, 1992, Focus 15(3):73-83; Feigner et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 84:7413; Stewart et al., 1992, Human Gene Therapy 3:267-275).
  • cationic lipids are also available, e.g., dimethyldioctadeclammonium bromide (DDAB); a biodegradable lipid 1, 2-bis(oleoyloxy)- 3-(trimethylammonio) propane (DOTAP); these liposomes may be mixed with a neutral lipid, e.g., L- ⁇ dioleoyl phosphatidylethanolamine (DOPE) or cholesterol (Choi), two commonly used neutral lipids for systemic delivery.
  • DOPE dioleoyl phosphatidylethanolamine
  • Choi cholesterol
  • DNA:liposome ratios may be optimized using the methods used by those of skill in the art (see e.g., Nicolau et al., 1987, Methods Enzymol.
  • the plasmid DNA coding for the genes or nucleic acids encoding one or more components resulting in the formation of a FRMS of the invention may be delivered via polycations, molecules which carry multiple positive charges and are used to achieve gene transfer in vitro, in vivo and ex vivo.
  • Polycations, such as polyethilenimine, may be used to achieve successful gene transfer (see e.g., Boletta et al., 1996, J. Am. Soc. Nephrol. 7:1728).
  • Recombinant viruses can also be used to deliver the components whose association results in the FRMS. Cells infected by these viruses or transformed by the viral genome will thus express the desired components.
  • a live recombinant vector or an inactivated recombinant viral vector expressing one or more component(s) described herein can be engineered.
  • viruses may be genetically engineered to express a component important in the formation of a FRMS. In some case, it may be desired that the recombinant viruses are either cold adapted, temperature sensitive, or attenuated.
  • viruses and viral vectors may be used to deliver the nucleotide sequences encoding one or more component(s) important to the formation of a FRMS of the present invention, a few examples of which are described below.
  • Retroviral vectors are commonly used to deliver genes to host cells. Retroviral vectors are extremely efficient gene delivery vehicles that cause no detectable harm as they enter the cells.
  • the retroviral nucleic acid may integrate into host chromosomal DNA allowing for long-term persistence and stable transmission to future progeny, such a vector would be useful for the delivery of one or more component(s) which result in the formation of a FRMS.
  • An example of an appropriate retroviral vector are lentiviruses which have the advantage of infecting and transducing non-dividing cells.
  • a lentiviral vector encoding a packagable RNA vector genome and operably linked to a promoter in which all the functional retroviral auxiliary genes are absent, is used to transfer the DNA encoding a component important in the formation of a FRMS of the present invention.
  • examples of such vectors are described in WO 98/17815, WO 98/17816 and WO 98/17817, each of which is incorporated herein by reference in their entirety.
  • non-integrating viral vectors which infect and transduce non-dividing cells such as adenoviral vectors may be used to deliver a component important in the formation of a FRMS.
  • Adenoviral vectors have several advantages since such vectors avoid risks associated with permanently altering the host cell genome or promoting insertional mutagenesis.
  • Adenoviruses are one of the best developed non-integrating viral vectors and can be used to transfer expression cassettes of up to 75 kb. Recombinant adenoviruses can be produced at very high titers is highly infectious and efficiently transfer genes to a wide variety of non-replicating and replicating cells and is further ideal for in vivo mammalian gene transfer.
  • Adenovirus-based vectors are relatively safe and can be manipulated to encode the desired component(s) and at the same time to be inactivated in terms of its ability to replicate in a normal lytic viral life cycle.
  • Adenovirus has a natural tropism for airway epithelia. Therefore, adenovirus-based vectors are particularly preferred for epithelial delivery applications.
  • the adenovirus-based gene therapy vector comprises an adenovirus 2 serotype genome in which the Ela and the Elb regions of the genome, which are involved in early stages of viral replication have been deleted and replaced by nucleotide sequences of interest.
  • the adenovirus —based gene therapy vector contains only the essential open reading frame (ORF3 or ORF6 of adenoviral early region 4 (E4) and is deleted of all other E4 open reading frames, or may additionally contain deletions in the E3 regions (see e.g. U.S. Patent No. 5,670,488, incorporated herein by reference in its entirety).
  • the adenovirus-based therapy vector used may be a pseudo-adenovirus (PAV), which contain no harmful viral genes and a theoretical capacity for foreign material of nearly 36 kb.
  • PAV pseudo-adenovirus
  • adeno-associated virus (AAV) systems may be used to deliver the component important in the formation of a FRMS of the present invention.
  • AAV has a wide host range and AAV vectors have currently have been designed which do not require helper virus. Examples of such AAV vectors are described in WO 97/17458.
  • Vaccinia viral vectors may be used in accordance with the present invention, as large fragments of DNA are easily cloned into its genome and recombinant attenuated vaccinia variants have been described (Meyer, et al., 1991, J. Gen. Virol. 72:1031-1038).
  • a vaccinia viral vector is used to deliver the components important to the formation of an FRMS such that the components are expressed in the recombinant vaccinia infected cell.
  • the components are human CD4, a co-receptor (e.g., CCR5 or CXCR4), and the HIV envelope protein.
  • infection of a cell with the recombinant vaccinia results in the expression of the components and formation of an HIV FRMS.
  • two different recombinant vaccinia viruses are constructed such that the first virus encodes the HTV env protein, and the second virus encodes human CD4 and a chemokine receptor.
  • the first virus is used to infect a first population of cells such that the infection results in the expression of the HIV env protein.
  • the second virus is used to infect a second population of cells such that the infection results in the expression of CD4 and the chemokine receptor.
  • Co-culturing of the first infected population of cells with the second infected population of cells results in the formation of an HIV FRMS.
  • the co-cultured cells may be cross-linked.
  • Orthomyxoviruses including influenza; Paramyxoviruses, including respiratory syncytial virus and Sendai virus; and Rhabdoviruses may be engineered to express mutations which result in attenuated phenotypes (see U.S. Patent Serial No. 5,578,473, issued November 26, 1996 incorporated herein by reference in its entirety). These viral genomes may also be engineered to express foreign nucleotide sequences, such as a component important in the formation of a FRMS of the present invention (see U.S. Patent Serial No. 5,166,057, issued November 24, 1992 incorporated herein by reference in its entirety).
  • Reverse genetic techniques can be applied to manipulate negative and positive strand RNA viral genomes to introduce mutations which result in attenuated phenotypes, as demonstrated in influenza virus, measles virus, Sindbis virus and poliovirus (see Palese et al., 1996, Proc. Natl. Acad. Sci. USA 93:11354-11358). These techniques may also be utilized to introduce foreign DNA, i.e., encoding a component or protein important in the formation of a FRMS to create recombinant viral vectors to be used in
  • Attenuated adenoviruses and retroviruses may be engineered to express a component important in the formation of a FRMS. Therefore, a wide variety of viruses may be engineered to deliver a component important in the formation of a FRMS of the present invention.
  • Bacteriophage may be used to specifically infects a bacterial cell (Soothill,
  • the non-viral DNA e.g., encoding a cell receptor
  • non-native viral DNA e.g., encoding a viral envelope protein
  • receptor(s), and/or co-receptor(s) used to construct the FRMS of the subject invention can be provided to cells by virions, virus-infected cells or chemically/genetically inactivated virions, viral vectors, viral replicons (i.e. non-replicating viral constructs, e.g. VEE replicons), virus-like particles produced by recombinant DNA methods or as naked DNA.
  • recombinant expression systems may employ regulatory
  • any of the methods previously described for the insertion of DNA or nucleic acid fragments into a vector may be used to construct expression vectors containing a gene or chimeric gene consisting of appropriate transcriptional translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and
  • expression of a nucleic acid sequence encoding a protein or peptide fragment may be regulated by a second nucleic acid sequence so that the protein or peptide is expressed in a host cell transformed with the recombinant DNA molecule.
  • expression of a viral envelope protein may be controlled by any promoter/enhancer element known in the art.
  • a promoter/enhancer may be homologous
  • Promoters which may be used to control the expression of a protein include, but are not limited to, the S V40 early promoter region (Benoist et al., 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-
  • promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Hereera-Estrella et al., 1984, Nature 310:115-120)
  • promoter elements from yeast or other fungi such as the Gal4- responsive promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol
  • elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Omitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399- 409; MacDonald, 1987, Hepatology 7:425-515); a gene control region which is active in
  • pancreatic beta cells pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), an immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436- 1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region
  • liver 15 which is active in liver (Pmkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639- 1648; Hammer et al., 1987, Science 235:53-58), alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene control region which is active in erythroid cells (Mogram et al., 1985, Nature 315:338-
  • a vector is used that comprises a promoter operably linked to a nucleic acid encoding a viral or cellular protein or chimeric protein and one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene).
  • a promoter operably linked to a nucleic acid encoding a viral or cellular protein or chimeric protein and one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene).
  • two or more promoters may be used to direct expression of two or more genes within a single plasmid.
  • the CMV immediate early (IE) promoter is used to direct expression of a nucleic acid encoding a viral or cellularprotein or chimeric protein.
  • Promoters can be inducible, or constitutive. Expression from certain promoters can be elevated in the presence of certain inducers; thus, for example, expression 35 of the genetically engineered protein chimeras may be controlled. Inducible promoters may be used to control expression of the proteins of the invention, such that the protein is produced only in the presence of the inducer.
  • the present invention also provides methods for stable expression of the components which result in the formation of an FRMS of the invention. For long term, high-yield production of recombinant proteins, stable expression is possible. For example, cell lines which stably express one or more cellular receptors and co-receptors for the virus,
  • engineered 5 may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter sequences, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. For example, following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in
  • the selectable marker in the recombinant plasmid confers resistance to the selection foci (e.g., by stably integrating the plasmid into their chromosomes) and allows cells to and grow to form which in turn can be cloned and expanded into cell lines.
  • This method may advantageously be used to engineer cell lines.
  • This method may advantageously be used to engineer cell lines which express
  • a number of selection systems may be used in generating stably-expressing cell lines, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska et al.,
  • DHFR which confers resistance to methotrexate (Wigler, et al., 1980, Natl. Acad. Sci. USA 77:3567; O ⁇ are, et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers
  • the present invention encompasses the expression of component(s) whose association results in the formation of the FRMS.
  • expression may be in primary cells, animal cells, and insect cell lines.
  • primary or secondary cells or cell strains may be used including but not limited to cells isolated from skin, bone marrow, liver, spleen, pancreas, kidney, adrenal and neurological tissue to name a few.
  • Other cells types that may be used in accordance with the present invention are immune cells (such as T-cells, B -cells, natural killer cells, etc.), macrophages/monocytes, adipocytes, pericytes, fibroblasts, neuronal cells, reticular cells etc.
  • secondary cell lines may be used, including, but not limited to hepatic cell lines, such as CWSV, NR, Chang liver cells, or other cell lines such as CHO, VERO, BHK, Hela, COS, MDCK, 293, 373, CaSki and W138 cell lines.
  • host cells comprise one or more cell receptors that facilitate binding or viral infection.
  • the cell is eukaryotic, preferably a cell line, preferably mammalian, and most preferably human may be used for the method of the invention.
  • Cells may be derived from human (e.g., HeLa cells), primate, mouse, rabbit, chicken, etc., although may also be from a transgenic non-human animal. Numerous eukaryotic cell lines may be purchased from ATCC (American Type Culture Collection, Rockville, MD). In a most preferred embodiment, eukaryotic cell is derived from a human. In other embodiments, the cell is derived from a mouse, monkey, or rat. Preferably non-tumor cell lines and autologous permissive cells are used in preparing the FRMS of the subject invention.
  • the present invention provides cells comprising one or more components which result in the formation of an FRMS of the invention.
  • the present invention also provides cells comprising all of the components required for the formation of the FRMS of the invention.
  • the present invention provides a cell that recombinantly expresses an envelope protein of an enveloped virus that functions in fusion of the viral envelope with a host cell membrane, or a mutant form of said envelope protein that is fusion-defective.
  • the cell expresses one or more cellular membrane proteins that function as receptors for said envelope protein.
  • the invention provides a cell that recombinantly expresses HIV gpl 60, human CD4 and a co-receptor for HIV.
  • the present invention also provides a cell line that recombinantly expresses an envelope protein of an enveloped virus that functions in fusion of the viral envelope with a host cell membrane, or a mutant form of said envelope protein that is fusion-defective.
  • the cell line expresses one or more cellular membrane proteins that function as receptors for said envelope protein.
  • the invention provides a cell line that recombinantly expresses HIV gpl 60, which cell line expresses CD4 and a co-receptor for HIV; said cell line lacking a functional protease that cleaves gpl 60 to produce gpl 20 and gp41.
  • cells comprising the FRMS of the invention are administered as an immunogen(s) to a subject (see Section 5.5, herein).
  • the cells when the subject is a human, the cells are human primary cells.
  • the cells are autologous.
  • any viral envelope protein containing wild type fusion activity is used to make the FRMS.
  • a fusion-defective envelope protein is used, as described in this section.
  • the present invention provides for the use of mutations to viral envelope proteins or host cell receptor or co-receptor proteins which mutations inhibit the completion of process of viral envelope and cell membrane fusion.
  • the invention provides fusion- defective mutations which do not allow completion of the process of viral envelope-cell membrane fusion, but which do result in the formation of a fusion-related molecular structure of the invention.
  • the fusion-defective mutations are used to construct epitopes comprising an FRMS.
  • association of the fusion defective envelope protein with the cellular receptor(s) results in the accumulation of the FRMS.
  • the fusion-defective mutations of the invention may be used in the formation of an FRMS.
  • Any technique for mutagenesis known in the art can be used to modify individual nucleotides in a DNA sequence, for purpose of making amino acid substitution(s) in the expressed peptide sequence, for creating/deleting restriction sites, or for adding affinity tags.
  • Such techniques include but are not limited to, chemical mutagenesis, in vitro site-directed mutagenesis (Hutchinson, C, et al., 1978, J. Biol. Chem 253:6551), oligonucleotide-directed mutagenesis (Smith, 1985, Ann. Rev. Genet. 19:423-463; Hill et al., 1987, Methods Enzymol.
  • a fusion-defective mutation may be constructed for any enveloped virus.
  • mutations are constructed that affect the ability to complete fusion. Selection of mutations may be based on published work, or based on molecular modeling from known or hypothetical structure predictions. Mutations known not to detrimentally affect envelope protein expression and transit to the cell surface will be preferred.
  • a fusion-defective mutant is confirmed by expressing the mutated gene in a cell (e.g., the methods of the invention) such as COS, 293T and assayed for fusion competence. Cells may then be assayed for cell surface expression of the mutant component (by methods known in the art such as, e.g., by flow cytometry or by live cell indirect immunofluorescence). Additionally, proteolytic processing of a mutant protein such as a mutant of HTV gpl 60 may be assayed by Western blot analysis or any other methods known in the art.
  • a mutant protein such as a mutant of HTV gpl 60 may be assayed by Western blot analysis or any other methods known in the art.
  • Fusion competency of mutant components may be assayed as described in Section 5.7, herein, (e.g., by syncytium formation assay, e.g., in the case of HIV, U87-CD4-co-receptor cell fusion assay).
  • binding-defective, fusion-defective or fusion-arrested mutant envelope proteins are tested for the ability to elicit primary isolate virus neutralizing antibodies in the transgenic mouse vaccination assay.
  • immunogens may comprise cells expressing the test mutant envelope protein cocultured with e.g. U87-CD4-CCR5 cells (when testing HIV related mutants).
  • mutations that elicit broad PI virus neutralization are developed as subunit and recombinant virus-based immunogens.
  • Table I provides a list of exemplary mutations which are provided for HTV. As will be apparent to one skilled in the art, similar mutations can be constructed for other enveloped viruses.
  • the bridging sheet of the gpl 20 core structure includes those of Kwong et al. (Kwong PD, et al, 1998, Nature 393:648-59; Kwong PD, et al, 1999, J Biol Chem. 274:4115-23) and regions of putative gp41/gpl20 interaction.
  • the FRMS of the subject invention are prepared using viral envelope proteins containing binding and fusion-related mutations.
  • the viral proteins bind host cell receptors, however, mutation causes the fusion process to be arrested before or during fusion of the viral envelope and host cell membrane.
  • the FRMS of the subject invention include epitopes resulting from the association of one or more viral envelope proteins and one or more cell membrane proteins, including those proteins which are fusion-defective, fusion-arrested or binding-defective so long as the mutant proteins when used in the methods of the invention result in an epitope elicits PI neutralizing antibodies.
  • Protein complexes arrested during the process of fusion can be isolated and used in the methods and compositions of the invention including but not limited to immunogens, diagnostics, kits, vaccines and compositions.
  • the FRMS comprise the major viral envelope protein of HIV- 1.
  • There are a variety of classes of fusion-related mutations which may be used in constructing the complexes of the subject invention.
  • the oligomeric envelope protein complex gpl60 binds initially to the CD4 receptor on the host cell. Conformational changes in both the envelope protein and CD4 receptor facilitate interaction with a co-receptor molecule on the host cell surface. Further conformational changes in the viral protein-CD4-co-receptor trimolecular complex allow exposure of a viral gp41 pre-hairpin intermediate and the insertion of the N-terminal gp41 hydrophobic fusion domain into the host cell membrane.
  • Helical heptad-repeat regions within the pre-hairpin intermediate subsequently collapse to form the trimeric, coiled-coil core of fusion active gp41.
  • the coiled-coil core drives the ultimate fusion of the apposed cell and virus membranes.
  • Viral envelope proteins with mutations that abrogate proteolytic cleavage of the gpl 60 precursor protein preventing liberation of the gp41 hydrophobic fusion domain can be used to construct the subject complexes.
  • certain mutations that alter the highly conserved lys/arg-X-lys/arg-arg site at the C-terminus of gpl 20 abrogates fusogenicity (see e.g., Lee CN, et al., 1994, AIDS Res. Hum. Retroviruses.10: 1065-9).
  • mutations that affect the N-terminal gp41 fusion peptide can be used in creating the complexes of the subject invention.
  • the hydrophobic N-terrninal region of gp41 mediates fusion by inserting into the cell membrane and destabilizing the lipid bilayer, perhaps by adopting a helical structure. Certain amino acid changes within this region render the envelope protein nonfusogenic. Synthetic peptides bearing these changes are either unable to bind to lipid bilayers unable to elicit fusion.
  • Two fusion-defective mutations in gp41 have been well characterized: V2E and GlOV (Kliger Y, et al., 1997, J Biol Chem.272:13496-505).
  • the former involves a polar substitution in the hydrophobic peptide, whereas the later may affect the helical structure assumed in the lipid bilayer.
  • These mutations can be introduced into the 168P envelope gene (gp41: ala-val- gly-ile- gly-val-leu-phe-leu- gly-phe-leu- gly-phe-leu- gly ]. by site-directed mutagenesis or any method known in the art and the envelope proteins tested for expression and fusogenicity. Further, envelope proteins having mutations that alter the coiled-coil core region of gp41 can be used to construct the structures of the subject invention.
  • the highly-conserved coiled-coil motif is found in proteins involved in fusion of many virus families, and similar structures have been identified in cellular proteins that mediate vesicular fusion.
  • Synthetic peptides that mimic either the N- or C-helical region e.g. DP 107 and DP 178) (Furuta et al., 1998, Nature Structural Biology 5:276-279.) potently neutralize virus infectivity, presumably by binding the cognate helical region and interfering with the collapses of the pre-hairpin intermediate.
  • the N- and C-helical regions of gp41 have also been saturated by mutagenesis.
  • Competent or mutated viral envelope protein as well as cell receptors and or co-receptors can be incorporated into viral vectors or diploid cells by methods known in the art including those described herein.
  • Viral genes encoding viral proteins are routinely cloned for expression in bacterial cells, in eucaryotic or procaryotic cells, or in viral or DNA vectors.
  • human cellular receptors can be cloned and expressed to produce models by which to study dangerous pathogenic diseases.
  • Viral genes or host receptors can be incorporated into foreign DNA by transfection or through the use of viral vectors.
  • FRMS of the subject invention can be formed as a result of the interaction of viral proteins and a variety of animal cellular components including but not limited by those listed above.
  • capture the FRMS in an immunogenic form that provides vaccine efficacy for primary viral isolates.
  • the FRMS of the subject invention result from interaction of one or more viral envelope proteins with one or more host cellular receptors and/or co-receptors.
  • complexes are "captured" by fixing or cross- linking the FRMS.
  • a FRMS formed in co-cultured cells expressing the viral and cellular components respectively, which result in a FRMA may be captured by fixation of the cells with a cross-linking agent.
  • cells transformed with a nucleic acid expressing a viral envelope protein and cells transformed with nucleic acids expressing host cellular receptors and co-receptors are cultured together.
  • the viral protein expressed on the surface of a first cell binds to the rece ⁇ tor(s) expressed on the surface of a second cell.
  • the cells are fixed at the initiation of this cell-cell interaction.
  • crosslinking "captures" the intermediate fusion complex and provides fusion-related determinants which may be isolated and use as, for example, vaccine components. Any method known in the art may be used to express the viral or cellular components of a fusion complex in a cell (See, for example, Section 5.1.1, herein).
  • Cross-linking reagents that can be used include but are not limited to formaldehyde glutaraldehyde, formalin, p-Azidobenzoyl hydrazide, N-(4-[p-Azidosalicyclamido]-butyl)-3 l (2'-pyridyldithio)-propionamide, Bis(beta- [4-azidosalicylamido]-ethyl)disulfide, 1 ,4-bismaleimidyl-2,3-dihydroxybutane, 1 ,6- Bismaleimidohexane, l,5-Difluoro-2,4-dinitrobenzene, Dimethyl adipimidate-2HCl, Dimethyl suberimidate-2HCl, Dimethyladipodimidate-2HCl, Dimethyl pimel
  • the cross-linking reagent is formaldehyde. In one specific embodiment low levels of formaldehyde (0.2%) are used in order to conserve antigenicity.
  • Formaldehyde in concentrations of from about 0.01% to about 8% can be used in preparing the complexes of the subject invention.
  • Other agents that can be used to cross-link fusing cells include but are not limited to glutaraldehyde (0.05-0.5%).
  • fixing or cross-linking conditions i.e., reagent used, concentration of reagents, time and temperature
  • concentration of reagents, time and temperature can be varied to determine optimal conditions for immunogenicity of the FRMS.
  • the complexes of the subject invention can be prepared by infecting human diploid cells in cell culture with, for example, recombinant vaccinia virus expressing viral envelope proteins and CD4/co-receptor (if not endogenously present). During fusion, the cells are cross-linked to capture the fusion-related structures and determinants.
  • the cells undergoing infection may be cross-linked in order to capture the FRMS.
  • a single cell may be engineered to express all of the components important for the formation of a FRMS.
  • such a cells or cells may be cross-linked or fixed in order to capture the FRMS.
  • the invention provides viral particles which are engineered to express in the viral envelope the cellular components or proteins important for FRMS formation.
  • the recombinant viral particles may be cross-linked to capture the FRMS formed withing the viral particle envelope.
  • the complexes need not be fixed or cross-linked. It has been found that the complexes of the subject invention form in cell lysates, in solution. Therefore, creation of the subject complexes by, for example, the simple lysis of cells transfected or infected with HIV-1 envelope protein as well as CD4/co- receptor where the FRMS form in solution. Cell lysis protocols are well known in the art (see, e.g., Sambrook et al., supra).
  • Cell lysis protocols may involve detergent lysis (e.g., 1% NP40) freeze thaw lysis, sonication lysis, or any method known in the art.
  • cell cultures are fixed at the onset of cell-cell interactions by fixation in ice cold 0.2% formaldehyde in phosphate buffered saline.
  • detergent lysis of cells involves the use of the detergent Brij 97.
  • the invention provides a molecular structure which is a cross- linked cellular molecular structure or is isolated from a cell lysate.
  • fusion-defective mutations which allow accumulation of the FRMS and allows capturing of the FRMS.
  • cells e.g. cross-linked cells
  • FRMS molecular structures comprising the FRMS may be isolated for use as immunogen.
  • the FRMS may be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.
  • the components important in the formation of a FRMS can be synthesized comprising an affinity tag which facilitates recovery and purification.
  • the peptide tag can be associated with any portion of the protein, so long as such association does not alter the epitope formation generated by association of the
  • such a chimeric protein comprising an affinity tag can be made by ligating a gene sequence coding for the component to the sequence encoding the peptide tag in the proper reading frame and recombinantly expressing the protein. Care should be taken to ensure that the modified gene remains within the same translational reading frame, uninterrupted by translational
  • peptide tags known in the art may be used in the modification of a protein, such as but not limited to the polyhistidine sequence (Petty, 1996, Metal-chelate affinity chromatography, in Current Protocols in Molecular Biology, Vol. 2, Ed. Ausubel et al., Greene Publish. Assoc. & Wiley Interscience), glutathione S-transferase (GST; Smith,
  • peptide tags are recognized by specific binding partners and thus facilitate isolation by affinity binding to the binding partner, which is preferably immobilized and/or on a solid phase surface.
  • affinity binding to the binding partner
  • many methods can be used to obtain the coding region of the above-mentioned peptide 5 tags, including but not limited to, DNA cloning, DNA amplification, and synthetic methods.
  • Some of the peptide tags and reagents for their detection and isolation are available commercially.
  • DNA sequences encoding desired peptide tags which are known or readily available from libraries or commercial suppliers are suitable in the practice of this 0 invention. These and other peptide tags are recognized by specific binding partners and thus facilitate isolation by affinity binding to the binding partner which can be immobilized onto a solid phase surface.
  • the chimeric protein gene product can be prepared using recombinant DNA techniques. For example, gene sequence encoding a component important in the formation of a FRMS can be introduced into a vector containing the 5 sequence of a peptide tag, such that the component gene is expressed as a peptide-tagged chimeric protein.
  • Peptide tags which may be recognized by specific binding partners, may be used for affinity binding to the binding partner immobilized on a solid phase surface.
  • a poly-histidine tagged fusion-related protein is constructed by insertion of a fusion-related protein gene or gene fragment into an expression vector such as one of the ⁇ ET15 series of vectors (Novagen), that express inserted sequences as chimeric proteins with N-terminal poly-histidine tags. Proteins which have a succession of six or more histidine residues at their amino or carboxyl terminus have a strong binding affinity to nickel. Poly-histidine-tagged chimeric proteins will bind specifically to the surface of a solid phase coated with chelated nickel. In a specific prefereed embodiment, microtiter plates coated with metal chelates are used to isolate the poly-histidine-tagged chimeric proteins (Pierce).
  • a system described by Janknecht, et al. allows for the ready purification of non-denatured chimeric proteins expressed in human cell lines (Janknecht, et al., 1991, Proc. Natl. Acad. Sci. USA 88, 8972-8976).
  • the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni 2+ nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.
  • an expression construct can be made by subcloning a fusion-related protein into the EcoRI restriction site of each of the three pGEX vectors (glutathione S-transferase expression vectors; Smith et al., 1988, Gene 7:31-40). This allows for the expression of a chimeric protein comprising the fusion-related protein linked to the GST binding domain in all three reading frames, such that, in one frame, the GST binding activity is maintained in the resulting chimeric protein.
  • a GST chimeric peptide has a strong binding affinity for its substrate, glutathione.
  • FRMS comprising a GST tag is separated from a binding mixture comprising a cellular lysate or fixed cells by contacting such mixture with a glutathione-linked solid phase surface, such as glutathione sepharose beads.
  • a glutathione-linked solid phase surface such as glutathione sepharose beads.
  • the GST-chimeric protein can be anchored to glutathione-agarose beads or a glutathione-sepharose column. The mixture is then added to the column or beads in a manner that allows interaction and binding to occur. At the end of the reaction period, unbound material can be washed away. The interaction between the chimeric protein and the glutathione-agarose beads allows isolation of the complex.
  • a chimeric protein may be readily purified by utilizing an antibody specific for the chimeric protein being expressed.
  • an affinity-tagged FRMS can be constructed by conjugation of an affinity compound to the fusion-related protein.
  • Affinity compounds can be used, such as, but not limited to, biotin, photobiotin, or other compounds known in the art.
  • affinity compounds or affinity tags can be conjugated to the fusion-related protein through a polyfunctional crosslinker, and preferably a bifunctional molecule.
  • the term polyfunctional crosslinker encompasses molecules having more than one functional group that reacts with a functional group on the fusion- related protein. Typically, such crosslinker forms covalent bonds with an amino or sulfhydryl group on a polypeptide.
  • biotin N-hydroxysuccinimide esters may be used.
  • This S-TAGTM system was developed commercially by Novagen, Inc.
  • the fusion-related proteins of the FRMS is tagged with S-peptides.
  • the invention provides examples of components of complexes which were tagged with the S-peptide at the C-terminal ends of the CD4, CCR5 or envelope protein molecules. Tagged complexes were readily isolated and purified by S-protein agarose affinity chromatography.
  • membrane-impermeable cross-linking reagents can be used to fix cells containing tagged complexes.
  • fixing cells containing tagged complexes with a membrane impermeable cross-linking agent facilitates avoiding inactivation of the cytoplasmic S-peptide tag.
  • the S-peptide sequence may be altered (ala-glu-thr-ala-ala-ala-ala- phe-glu-arg-gln-his-met-asp-ser) so that it no longer contains vulnerable lysine residues and thus can be fixed with formaldehyde without resulting in inactivation of the cytoplasmic tag.
  • Fusing cells can be fixed with a wide range of membrane impermeable cross-linking reagents including, but not limited to BS 3 and DTSSP (homobifunctional N-hydroxysuccinimidyl (NHS) esters that react through amines to form either non-cleavable or reversible linkages, respectively); Sulfo-SMPB (heterobifunctional NHS ester and maleimide to irreversibly cross-link amine and sulfhydryl groups); Sulfo-SANPAH and SASD (heterobifunctional NHS ester and photoreactive phenylazide cross-linkers which form either non-cleavable or reversible linkages, respectively) (Pierce Chemical Company).
  • BS 3 and DTSSP homobisulfo-SMPB (heterobifunctional NHS ester and maleimide to irreversibly cross-link amine and sulfhydryl groups)
  • Sulfo-SANPAH and SASD heterofunctional NHS ester and photoreactive phenyla
  • Tagged complexes are readily purified providing an isolated preparation of the fusion-related components which may be used for example, for inclusion in vaccine formulations. Purified or isolated tagged complexes can also be used as diagnostic standards for in vitro assays. Further, tagged complexes permit the functional analysis of envelope-mediated fusion.
  • the invention provides a method of purifying a protein complex comprising an envelope protein of human immunodeficiency virus type 1 functionally interacting with human CD4 and human CCR5 including the steps of: a) tagging the complex with a peptide sequence to facilitate subsequent purification; and b) isolating the tagged complex.
  • the invention provides an isolated protein complex comprising an envelope protein of human immunodeficiency virus type 1 functionally interacting with human CD4 and human CCR5.
  • TYPES OF FRMS any enveloped virus may be used in the methods of the invention in order to construct or use the FRMS.
  • an important use of the FRMS of the invention is as vaccine immunogens.
  • One advantage of the vaccines comprising FRMS is that these immunogens provide significantly higher neutralization rates of primary isolates.
  • the enveloped viruses that can be used include but are not limited to the families of Retroviridae, Rhabdoviridae, Coronaviridae, Filoviridae, Arenaviridae, Poxviridae, Bunyaviridae, Flaviviridae, Togaviridae, Orthomyxoviridae, Paramyxoviridae, Herpesviridae, and Iridoviridae.
  • a retroviral FRMS is formed by the methods of the invention.
  • the FRMS of the invention comprises the major viral envelope immunogen of human immunodeficiency virus type 1 (HTV-1) and arises from interaction with the host cellular receptor for HTV-1 and a host cellular co-receptor.
  • the host cellular co-receptor can be CCR5, CXCR4, CCR3, CCR2b or any other known in the art.
  • An exemplified FRMS of the present invention results from interaction of the HIV-1 isolate 168P viral envelope protein arising from interaction with the host cellular receptor CD4, and the host cellular co-receptor CCR5. It should be apparent to those skilled in the art that other recombinant HIV envelope proteins, including those that act independently of CD4, could be used to prepare FRMS within the scope of the subject invention.
  • the immunogens of the subject invention are prepared by co-culturing envelope-protein expressing COS-7 cells (LaCasse et al. 1998, Science, 283:357-360) and cells expressing the human CD4 receptor and CCR5 co-receptor (U87-CD4-CCR5).
  • the envelope-expressing cells are harvested using 0.5 mM EDTA 24 hr after transfection (30-60% transfection efficiency) and co-cultured with an equal number of U87-CD4-CCR5 target cells. Progress towards fusion is assessed by staining envelope-expressing cells and monitoring their incorporation into multinucleated syncytia microscopically.
  • Fusion is complete within 12-24 hr. Complexes are formed immediately. Cells fixed after 1-5 hrs of co-culture are at an estimated 10-30% of maximal syncytium formation. This early time point in fusion was chosen initially in order to capture the transitional intermediates that lead to fusion. Other time points (e.g. 10 hr, 24 hr or greater) can also be used to obtain the fusion-related complexes of the subject invention. Complexes from later points in the fusion process may reveal still further neutralizing epitopes and can be used to map appearance and course in time of critical immunogens. In other embodiments, Flavivirus FRMS is generated by the methods of the invention.
  • Viruses within the Flavivirus family include, for example, Hepatitis C Virus (HCV), Dengue virus, Yellow Fever virus, Tick-borne Encephalitis virus, and Bovine Viral Diarrhea virus.
  • HCV Hepatitis C Virus
  • the Flaviviruses are similar to the Togaviridae which include the alphaviruses (e.g., Venezuelan Equine Encephalitis virus, Sindbis virus, Semliki Forest virus) and Rubella virus.
  • the Flaviviruses enter target cells via receptor-mediated endocytosis followed by pH-induced fusion within the endosome.
  • Viruses within the Flavivirus family encode an envelope (E) protein which is proteolytically cleaved in many family members to mature El and E2 proteins.
  • E envelope
  • the E2 protein is the receptor binding moiety (binding the cellular membrane protein CD81) and El is the putative viral fusion protein.
  • a Flavivirus or Togavirus FRMS is formed by the methods of the invention.
  • an HCV FRMS of the invention results from the association of El, E2 and CD81.
  • the HCV El and E2 proteins can be co-expressed in an acceptable cell substrate and will become localized in the cell endoplasmic reticulum (ER) and not significantly on the cell surface, hi one embodiment, these cell cultures are incubated in medium buffered to pH 5 to 6.8 in order to trigger E1E2 fusion of the intracellular membrane. The cultures are treated with a cross-linking agent to capture the intermediate fusion-competent structures, and used directly (or upon isolation of intracellular ER membranes) as vaccine immunogen.
  • the disrupted intracellular ER membranes containing E1E2 protein are isolated as everted micelles and then incubated with an appropriate permissive cell expressing the E2 receptor, CD81.
  • ElE2-containing micelles are internalized and El -mediated fusion occurs in the endosome.
  • Cells are then cross-linked and used for example, as vaccine immunogens.
  • E1E2 proteins are engineered to alter ER retention signals and thus allow expression of E1E2 proteins on the cell surface thus obviating the need to isolate ER membranes.
  • recombinant DNA derived HCV virus-like particles or HCV E1E2 containing pseudotyped virions can be produced and triggered for fusion by incubation with receptor-expressing cells in medium adjusted to pH 5-6.8.
  • the cultures are treated with a cross-linking agent such as formaldehyde and the FRMS is used as a vaccine immunogen.
  • virions can be incubated with CD81 -expressing cells; internalized virions will be induced to fuse within the endosome and can be captured by cross-linking treatment for use as a vaccine immunogen of the invention.
  • an orthomyxovirus FRMS is generated by the methods of the invention.
  • the orthomyxoviridae family includes all influenza viruses, including but not limited to, influenza A, influenza B and influenza C.
  • influenza FRMS elicits neutralizing antibodies against a wide variety of flu strains and would allow for a drift-independent flu vaccine.
  • the Orthomyxoviruses enter target cells via receptor-mediated endocytosis and fusion within the endosome.
  • the viral neuraminidase (NA) protein functions as the sialic acid receptor binding protein (a ubiquitously expressed cell surface carbohydrate), and the hemagglutinin (HA) protein functions in pH-induced fusion.
  • NA neuraminidase
  • HA hemagglutinin
  • influenza FRMS is generated by the methods of the invention.
  • Influenza FRMS is generated by the methods similar to those described above for the Flaviviruses and include pH-triggered HA-mediated fusion between appropriate cells or between cells and isolated cell membranes or virion particles, capturing the complex may be performed, for example, with a cross-linking agent allowing NA-mediated endocytosis and subsequent endosomal fusion to be captured.
  • a paramyxo virus FRMS is generated by the methods of the invention.
  • the Paramyxovirus family encompasses several subgroups of significant medical and veterinary importance, including but not limited to, MorbiUiviruses (measles virus, Canine Distemper virus, Rinderpest virus), Rubulaviruses (Mumps virus, Newcastle Disease), paramyxoviruses (human and bovine parainfluenza), and Pneumoviruses (Respiratory Syncytium virus). These viruses are similar to the Orthomyxoviruses, except that Paramyxovirus fusion occurs at the cell surface rather than in the endosome, and is pH independent.
  • the neuraminidase- hemagglutinin (HN) (or simply hemagglutinin (H)) protein mediates cell attachment whereas the fusion (F) protein mediates virus-cell or cell-cell fusion.
  • HN neuraminidase- hemagglutinin
  • F fusion protein
  • SUBSTITUTE SHEET (RULE 26 ⁇ mediates membrane fusion.
  • cells expressing H and F proteins from MV are co-cultured with cells expressing CD46 (and currently unidentified co- receptors) and result in cell-cell fusion that can be captured by cross-linking or other methods described herein.
  • the co-receptor may be expressed on fusion-permissive cells expressing exogenus CD46. Specific embodiments (as described for HIV and other viruses above) may also be used.
  • a herpesvirus FRMS is generated by the methods of the invention.
  • the Herpesviruses comprise a large family that include members of significant medical and veterinary importance.
  • the human herpesviruses include, but are not limited to, HSV 1 and HSV 2, Varicella-zoster virus, Epstein-Ban virus, Cytomegalovirus, and Kaposi's Herpesvirus HHV 8.
  • binding and entry is a complex process involving several viral glycoproteins (gD, gC, and gH/gL) and several cell receptors and adhesion molecules (glycosaminoglycans and Herpesvirus entry mediator (Hve) proteins A- C). Binding and fusion occur on the cell surface in a pH-independent manner.
  • HSV FRMS is constructed using a cell expressing the cellular receptors and adhesion molecules (e.g. human MRC5 cells) and co-culturing such cells with cells expressing the HSV glycoproteins gD, gC, gH, and gL.
  • Cell-cell fusion is preferably arrested by fixation with a cross-linking agent, to allow capturing of the FRMS.
  • viral proteins and host cellular receptors can be combined to form the subject FRMS for viruses including Herpes virus, pox viruses, paramyxovirus, measles, mumps, rubella, respiratory syncytial virus, influenza, Hepatitis C, ebola and flaviviruses such as Dengue and Yellow Fever.
  • viruses including Herpes virus, pox viruses, paramyxovirus, measles, mumps, rubella, respiratory syncytial virus, influenza, Hepatitis C, ebola and flaviviruses such as Dengue and Yellow Fever.
  • the FRMS of the subject invention can include viral proteins from viruses of veterinary importance including rabies, feline leukemia, feline immunodeficiency virus and rinderpest.
  • Table II presents an exemplary list of the cellular receptor(s) for particular enveloped viruses, which when expressed along with the viral envelope protein and allowed to associate with the envelope protein results in FRMS formation.
  • viral diseases that can be treated or prevented by the methods of the present invention include, but are not limited to, those caused by hepatitis type C, influenza, varicella, herpes simplex type I (HSV-I), herpes simplex type II (HSV-II), rinderpest, respiratory syncytial virus, cytomegalovirus, echinovirus, arbovirus, hantavirus, mumps virus, measles virus, rubella virus, human immunodeficiency virus type I (HIV-l), human immunodeficiency virus type II (HIV-2), any togaviruses (such as Dengue virus), alphaviruses, flaviviruses, coronaviruses, rabies virus, Marburg viruses, ebola viruses, parainfluenza virus, orthomyxoviruses, bunyaviruses, arenaviruses, human T cell leukemia virus type I, human T cell leukemia virus type II, simian immunodeficiency virus
  • Table III presents an exemplary list of envelope proteins for particular families of enveloped viruses, which when expressed along with the cellular receptor protein(s) and allowed to associate with the cellular receptor protein(s) results in FRMS formation.
  • a triple-stranded coiled-coil structure of Orthomyxoviridae (such as Influenza), Filoviridae (such as Ebola), or Retroviridae (such as HIV) facilitates the formation of FRMS.
  • Orthomyxoviridae such as Influenza
  • Filoviridae such as Ebola
  • Retroviridae such as HIV
  • synthetic peptides may be used to inhibit viral infection.
  • synthetic peptides that comprise either of the gp41 helical coils are able to bind the cognate helical region and broadly inhibit viral infectivity (see e.g., Wild, C, et al., 1992, Proceedings of the National Academy of Sciences USA 89:10537; Furuta, R.A., et al., 1998, Nature Structural Biology 5:276).
  • neutralizing antibodies to FRMS immunogens may likewise target structures involved in the activation of fusion.
  • viral strains may be used which do not require a host cell receptor, but require only a host cell co-receptor for association with the virus.
  • an HIV strain which does not require CD4 for viral binding may be used in the methods of the invention (see e.g., Hoxie, et al., 1998, J. Reprod. Immunol. 41:197-211.). Therefore, when using such a strain, expression of CD4 is not necessary.
  • the subject invention also concerns methods for vaccinating an individual or animal to raise an immune response to and prevent infection by a virus.
  • the FRMS of the subject invention can be presented to the vaccinee by several means.
  • the FRMS described above can be administered to a vaccinee as fixed cells combined with an adjuvant. Further, isolated and purified FRMS can be administered to a vaccinee.
  • FRMS can be prepared in situ by the simultaneous immunization of a vaccinee with transfected cells expressing viral protein and transfected cells expressing host cellular receptors and/or co-receptors.
  • vectors containing DNA encoding viral proteins and vectors containing DNA encoding receptor proteins can be used in this immunization strategy.
  • Vectors can include viral vectors such as vaccinia and vectors used in DNA immunization. After simultaneous immumzation, interaction between the viral protein and host cellular receptor protein occurs in vivo forming the FRMS of the subject invention and thereby exposing the vaccinee to the unique epitopes capable of eliciting neutralizing antibodies.
  • Another method by which the FRMS can be formed in situ includes utilizing the receptors and co-receptors on host cells.
  • transfected cells expressing the HTV glycoprotein or vectors containing DNA encoding the protein are injected into or targeted (e.g. by VEE or other vectors) the lymph node of a host.
  • the viral protein binds and initiates fusion in vivo to host cells having viral receptors and co-receptors to form the FRMS whereby the vaccinee is exposed to the newly formed neutralizing epitopes.
  • a vaccine formulation comprises an isolated protein complex comprising an envelope protein of human immunodeficiency virus type 1 functionally interacting with human CD4 and human CCR5, and a pharmaceutically acceptable carrier.
  • the invention provides a method of immunizing an animal to a virus comprising the steps of administering to the animal a vaccine formulation comprising a protein complex comprising one or more viral proteins functionally interacting with one or more host cellular receptors or co-receptors to mediate viral binding, entry and/or infection; whereby neutralizing antibodies to the virus is generated.
  • the invention provides a vaccine formulation comprising (a) a first nucleic acid encoding an envelope protein of an enveloped virus; and (b) a second nucleic acid encoding one or more cellular membrane proteins, which envelope protein and cellular membrane proteins are necessary and sufficient under suitable conditions for fusion of said envelope of the virus with a cell membrane containing said cellular membrane proteins, such that the envelope protein and cellular membrane proteins are expressed in the subject and neutralizing antibodies to the virus are produced; and (c) a pharmaceutically acceptable carrier.
  • the invention provides a method of treating a host that has been exposed to a virus, or preventing infection of a host by said virus, the method comprising the steps of administering to the host antibodies generated by immunizing an animal with an isolated protein complex comprising an envelope protein of human immunodeficiency virus type 1 functionally interacting with human CD4 and human CCR5. in an amount effective to treat or prevent infection of said host.
  • the invention provides a method of preparing a protein complex comprising one or more viral proteins functionally interacting with one or more host cellular receptors or co-receptors to mediate viral binding, entry and/or infection, including the steps of: a) culturing a first cell expressing one or more viral proteins; b) culturing a second cell expressing one or more host cellular receptors or co-receptors for said one or more viral proteins' c) co-culturing the first and second cells; d) fixing said co- culture during cell-cell fusion; and e) isolating the fixed cells.
  • the patient or subject to which the vaccine is administered is preferably a mammal, most preferably a human, but can also be a non-human animal including but not limited to cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats.
  • the patient or subject to which the vaccine is administered can also be a non- human wild animal including but not limited to lion, cheetah, elephants, giraffe, wildebeest, leopards, panthers, etc.
  • the invention provides a means of wildlife management, and provides a method of preventing or treating a wild animal or animal population which has a high degree of inbreeding such that said populations are highly susceptible to viral disease.
  • the subject is a human.
  • said human has a high risk of HIV infection.
  • the subject is a domestic animal.
  • the present invention thus provides a method of immunizing an animal, or treating or preventing viral diseases or disorders in an animal, comprising administering to the animal an effective immunizing dose of a vaccine of the present invention.
  • the vaccine formulations of the present invention can also be used to produce antibodies for use in passive immunotherapy, in which short-term protection of a host is achieved by the administration of pre-formed antibody directed against a heterologous organism.
  • Vaccination of mice with immunogens comprising FRMS of the subject invention elicits the production of neutralizing antibodies by immunized animals.
  • the complexes are administered as a vaccine comprising fixed whole cells formulated with an adjuvant. It would be apparent to one skilled in the art however that other vaccine strategies can be used in practicing the subject invention.
  • isolated and purified FRMS and/or epitopes thereof can be administered as subunit vaccines.
  • genes encoding the functional complexes can be constructed and placed in vectors or plasmids for use in live vector or DNA plasmid vaccines.
  • virus vaccine formulations of the invention comprise an effective immunizing amount of one or more FRMS as a vaccine immunogens of the invention and a pharmaceutically acceptable carrier or excipient. Boosting is also contemplated.
  • vaccine compositions of the invention can comprise "pharmaceutically acceptable carriers".
  • pharmaceutically acceptable carriers are substances which do not interfere with the operation of the immunogen and are non-toxic to the animal.
  • Pharmaceutically acceptable carriers include but are not limited to saline, buffered saline, dextrose, water, glycerol, sterile isotonic aqueous buffer, oil-on-water or water-in-oil emulsions, aqueous compositions, liposomes, microbeads, microsomes or adjuvant compounds and combinations thereof.
  • a physiologically balanced culture medium containing one or more stabilizing agents such as stabilized, hydrolyzed proteins, lactose, etc.
  • the carrier is preferably sterile.
  • the formulation should suit the mode of administration.
  • the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
  • Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.
  • a lyophilized fusion-competent complex of the invention is provided in a first container; a second container comprises diluent consisting of an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).
  • an effective immunizing amount is that amount sufficient to produce an immune response to the complex in the host to which the fusion-dependent complex, or vaccine immunogen, is administered.
  • an effective immunizing amount of a vaccine immunogen for a human subject of the present invention is within the range of 10 to 100 mg per kilogram body weight, more preferably 0.1 tolOmg per kilogram body weight.
  • Boosting is possible but not prefened.
  • the exact amount of vaccine immunogen utilized in a given preparation is not critical, provided that the minimum amount necessary to provoke an immune response is given.
  • a dosage range of as little as about 10 ⁇ g, up to amount a milligram or more, is contemplated.
  • individual dosages may range from about 50-650 ⁇ g per immunization. In other embodiments, dosing is dependent upon the formulation of the vaccine immunogen (e.g. purified mimitope, vs.
  • the vaccine formulation comprises an effective immunizing amount of the FRMS immunogen, preferably in combination with an immunostimulant; and a pharmaceutically acceptable carrier.
  • immunostimulant is intended to encompass any compound or composition which has the ability to enhance the activity of the immune system, whether it be a specific potentiating effect in combination with a specific immunogen, or simply an independent effect upon the activity of one or more elements of the immune response.
  • immunostimulant compounds in vaccine compositions are the adjuvants alum or muramyl dipeptide (MDP) and its analogues. Methods of utilizing these materials are known in the art, and it is well within the ability of the skilled artisan to determine an optimum amount of stimulant for a given viral vaccine. It may also be desired to use more than one immunostimulant in a given formulation.
  • purified immunogens or complexes vaccines can be carried out by standard methods.
  • the purified protein(s) should be adjusted to an appropriate concentration, formulated with any suitable vaccine adjuvant and packaged for use.
  • suitable adjuvants may include, but are not limited to: mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum, and MDP.
  • the immunogen may also be incorporated into liposomes, or conjugated to polysaccharides and/or other polymers for use in a vaccine formulation.
  • the complex is a hapten, i.e., a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response
  • the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it.
  • the hapten-carrier may be formulated for use as a vaccine.
  • Effective doses (immunizing amounts) of the vaccines of the invention may also be extrapolated from dose-response curves derived from animal model test systems. Accordingly, the present invention provides a method of treating or preventing infection by a virus in a subject comprising administering to the subject an immunogenic amount of the FRMS effective to treat or prevent infection by the virus. In a specific embodiment, the present invention provides a method of treating or preventing infection by HIV in a human comprising administering to the human an immunogenic amount of the FRMS effective to treat or prevent infection by HIV. The present invention also provides a method of treating or preventing infection by a virus in a subject comprising administering to the subject an amount of the FRMS effective to treat or prevent infection by the virus. In a specific embodiment, the invention provides a method of treating or preventing infection by HIV in a human comprising admimstering to the human an amount of the monoclonal antibody effective to treat or prevent infection by HIV.
  • FRMS polyclonal and monoclonal antibodies reactive to a FRMS of the invention.
  • FRMS its fragments or other derivatives, or analogs thereof, may be used as an immunogen to generate antibodies which immunospecifically bind such an immunogen.
  • Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library.
  • the subject invention also concerns methods for generating an immune response, such as antibody production, in an animal.
  • an animal is administered a FRMS of the invention.
  • the FRMS comprises the HTV envelope protein and arises from interaction with CD4 and CCR5.
  • the FRMS is administered in a manner such that an immune response is produced in the animal to the immunogen.
  • antibodies to epitopes on the FRMS are produced. More preferably, the antibodies produced include neutralizing antibodies. In a highly prefened embodiment, the antibodies produced are capable of neutralizing a wide variety of primary isolates of the virus.
  • polyclonal antibodies to a FRMS or derivative or analog may be obtained.
  • various host animals can be immunized by injection with the native FRMS, or a synthetic version, or derivative (e.g., fragment or chimera) thereof, including but not limited to rabbits, mice, rats, etc.
  • adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvurn.
  • BCG Bacille Calmette-Guerin
  • corynebacterium parvurn any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used.
  • monoclonal antibodies can be produced in germ-free animals (see e.g., PCT US90/022548).
  • human antibodies may be used and can be obtained by using human hybridomas (Cole et al, 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, in Monoclonal
  • spleens from mice immunized with FRMS are harvested and splenocytes are isolated by teasing the spleen apart in culture medium.
  • Splenocytes are fused with HPRT-negative mouse myeloma cells using polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • Antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
  • such fragments include but are not limited to, the F(ab') 2 fragment which can be produced by pepsin digestion of the antibody molecule, the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments.
  • Fab fragments from combinatorial libraries are also contemplated in the invention (see e.g., Chanock et al., 1993, Infect Agents Dis. 2:118-31).
  • screening for the desired antibody can be accomplished by techniques known in the art (e.g., enzyme-linked immunosorbent assay or ELISA). For example, to select antibodies which specifically recognize FRMS, one may assay generated hybridomas for a product which binds to a FRMS epitope and which does not bind to the epitopes generated by other proteins. For selection of an antibody that specifically binds a first FRMS homolog but which does not specifically bind a different FRMS homolog, one can select on the basis of positive binding to the first FRMS homolog and a lack of binding to the second FRMS homolog. Screening of antibodies may also be performed by functional assays such as virus neutralization assay, such as those known in the art or described herein.
  • functional assays such as virus neutralization assay, such as those known in the art or described herein.
  • Antibodies specific to a domain of a FRMS is also provided.
  • Antibodies specific to an epitope of a FRMS protein are also provided.
  • the generated antibodies may be isolated by standard techniques known in the art (e.g., immunoaffmity chromatography, centrifugation, precipitation, etc.) and used in diagnostic immunoassays.
  • the antibodies may also be used to monitor treatment and/or disease progression.
  • Any immunoassay system known in the art, such as those listed supra, may be used for this purpose including but not limited to competitive and noncompetitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme-linked immunosorbent assays), "sandwich” immunoassays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays and immunoelectrophoresis assays, to name but a few.
  • the FRMS of the subject invention when used as immunogens are capable of eliciting neutralizing antibody to viral pathogens.
  • the FRMS elicit neutralizing antibody to a wide variety of primary isolates of the virus.
  • the FRMS elicit neutralizing antibody to primary isolates of HIV-l.
  • Neutralizing antibodies while not elicited by static HIV envelope protein, are able to bind at least weakly to static envelope and are carried with the envelope protein through the binding and fusion process, during which the antibodies complete their high-affinity bmding to critical intermediate structures.
  • Such neutralizing antibodies can be, in effect, transported to the critical site to be available at the critical moment regardless of the cellular site of action, in particular regardless of the cellular site of membrane fusion (either at the cell surface or at internal membranes such as the endosomal membrane).
  • viral envelope proteins can serve as a vector to bring antibodies (e.g. linked to e.g. toxin, other protein, vaccine immunogens) into the cell, into the cytoplasm or into the histocompatibility complex presentation pathway.
  • Hybridoma cell supernatants of the invention can be assayed for the ability to neutralize the homologous virus as well as for the ability to neutralize a range of genetically diverse viruses.
  • the ability to neutralize genetically diverse viruses suggests recognition by the mAb of a conserved determinant.
  • mAb can be tested for inhibition of envelope-mediated cell-cell fusion.
  • MAb can also be assayed for the ability to bind and/or immunoprecipitate envelope protein and envelope protein-containing receptor-associated complexes. Of particular interest are those mAb that are specific for fusion-dependent epitopes and bind only weakly, if at all, to static envelope protein.
  • hybridomas are identified using high-throughput screening assay to detect PI virus neutralization, and mAbs are characterized to determine the breadth and molecular targets of PI virus neutralization.
  • the antibodies produced by the methods of the invention are used individually (e.g. a single mAb) or in combination (e.g., one or more mAbs directed to the same or different epitopes).
  • Combinatorial use of antibodies may include multiple mAbs directed to the same virus or to different viruses.
  • antibodies of the invention or the derivatives or analogues thereof to bind FRMS of the invention and thereby interfere with viral infection can be assayed by various methods.
  • Binding can be assayed by means well-known in the art. For example, bioassays may be performed in which cells known to be expressing a chemokine receptor are exposed to the mAb derivative or analogue to be tested and assayed for a known effect (e.g., signal transduction).
  • a known effect e.g., signal transduction
  • mAb, derivatives or analogues can be tested for the ability to bind chemokine receptors, host cell receptors or viral envelope proteins by procedures, including but not limited to, protein affinity chromatography, affinity blotting, immunoprecipitation, cross-linking, and library based methods such as protein probing, phage display, and the two-hybrid system (see, generally, Phizicky et al., 1995, Microbiol. Rev. 59:94-123).
  • High throughput screening for mAb, derivative or analogue binding may be performed by methods known in the art, including but not limited to flow cytometry.
  • cells that express human CD4 and one of the HIV co-receptors are treated with biotinylated mAb, derivative, or analogue and cell surface binding to the FRMS is detected with an avidin FITC conjugate.
  • flow cytometry system may be used in a competitive binding assays using the monoclonal antibodies of the invention in the following manner or by any method known in the art.
  • a mAb of the invention is labeled and examined for the ability to bind an FRMS of the invention compared with the ability of a o test antibody to bind to the same FRMS.
  • Test antibodies of the invention may be derived from samples such as serum from a subject, or manufacturing samples such as hybridoma supernatants.
  • the anti- viral activity exhibited by the mAb, mAb derivative and/or analogue of the invention may be measured, for example, by easily5 performed in vitro assays, which can test the compound's ability to inhibit syncytia formation or to inhibit infection by cell-free virus and assess the effects of the compound on cell proliferation and viability. Applying these assays, the relative anti-viral activity that a mAb, derivative and/or analogue exhibits against a given virus or strain of immunodeficiency virus formulation best suited for viral and strain specific inhibitory0 activity can be determined.
  • a cell fusion assay is used to test the ability of mAb, derivative or analogue, to inhibit virus-induced syncytia formation in vitro, m a specific embodiment, a cell fusion assay is used to test the ability of a mAb derivate or analog of the invention to inhibit HIV-induced syncytia formation in vitro.
  • an5 assay involves culturing uninfected CD4 + cells in the presence of chronically HlV-infected cells and the composition containing the mAb, derivative or analogue to be assayed. For each, a range of concentrations may be tested.
  • This range should include a control culture wherein no mAb, derivative and/or analogue has been added. Standard conditions for culturing, well known to those of ordinary skill in the art, are used. After incubation for an0 appropriate period, such as, for example, 24 hours at 37 °C, the culture is examined microscopically for the presence of multinucleated giant cells, which are indicative of cell fusion and syncytia formation.
  • an in vitro infectivity assay is performed using primary macrophages and the macrophage-tropic isolate HFV-l BaL , the first described5 macrophage-tropic HTV-l isolate (see, Gartner et al., 1986, Science 233:215).
  • primary macrophage cells isolated according to methods known in the art are infected with HTV-l BaL that has been propagated and maintained only in primary macrophages.
  • the input immunodeficiency virus is incubated with primary macrophages in the presence of concentrations of the mAb, derivative, or analogue to be tested. After a defined period of infection, unbound virus is removed by washing, and the cells are placed in culture.
  • the level of virus replication in this assay may be assessed by techniques known in the art, including but not limited to, measuring reverse transcriptase (RT) levels, or the release of extracellular p24 core antigen at different days post-infection.
  • a constant level of inhibition of viral infection or replication is determined by measuring output HTV p24 levels (or another indicator of viral infection or replication, such as for example, RT) relative to control assays performed in the absence of the mAb, derivative or analogue.
  • the iAb derivative or analogue reduces levels of virus, as measured by, for example, p24, by > 50% relative to control assays carried out in the absence of test compound.
  • RT activity may be tested by monitoring cell-free supernatant using standard techniques such as those described by, for example, Goff et al. (Goff et al., 1981, J. Virol. 38:239-248) and Willey et al. (Willey et al., 1988, J. Virol. 62:139-147).
  • a mAb of the invention is assayed in a primary isolate neutralization assay.
  • a variety of neutralization assays are known in the art, and are within the scope of the invention.
  • mAbs of the invention are assayed in a focus assay.
  • test antibody is incubated with a measured amount of virus prior to the addition of the virus to host cells. Infection of the host cells is measured by staining said cells by immunohistochemical methods known in the art using an antibody specific for the viral protein(s). Generally, a control assay is performed in parallel in which no test antibody is used.
  • Test antibody which inhibits (e.g., prevents or decreases) infection compared to the control infection is indicative of a neutralizing antibody.
  • a PBL assay can be used to assay neutralization by a test antibody.
  • test antibody is incubated with a measured amount of virus prior to the addition of the virus to host cells. Host cell cultures are allowed to incubate for a period of days, and infection is assayed by measuring the virions present in a sample of host cell supernatant.
  • a control assay is performed in parallel in which no test antibody is used.
  • Test antibody which inhibits (e.g., prevents or decreases) infection compared to the control infection is indicative of a neutralizing antibody.
  • the present invention encompasses the use of a non-human transgenic animal which expresses one or more components whose association results in the formation of the FRMS of the invention.
  • the components whose association results in the formation of the FRMS may include those listed in Table II and Table III, herein.
  • the transgenic animal models of the invention may be used as Tolerance models and/or Infection models. In the case of Tolerance models, it is prefened that all of the cellular components important to the formation of the FRMS are expressed in the transgenic animal. In the case of Infection models, one or more of the components important for the formation of the FRMS may be expressed such that the transgenic animal is capable of infection by the virus to which the FRMS is derived.
  • Animals of any species including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, sheep, and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals expressing a component which results in the formation of a FRMS.
  • transgenic refers to animals expressing one or more components whose association results in the formation of the FRMS gene sequences from a different species (e.g., mice expressing human sequences encoding one or more component whose association results in the formation of a FRMS), as well as animals that have been genetically engineered to over express endogenous (i.e., same species) sequences encoding one or more component whose association results in the formation of a FRMS or animals that have been genetically engineered to no longer express endogenous gene sequences encoding one or more component whose association results in the formation of a FRMS (i.e., "knock-out" animals), and their progeny.
  • Any technique known in the art may be used to introduce an gene encoding one or more component whose association results in the formation of a FRMS transgene into animals to produce the founder lines of transgenic animals.
  • Such techniques include, but are not limited to pronuclear microinjection (Hoppe and Wagner, 1989, U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten, et al, 1985, Proc. Natl. Acad. Sci., USA 82, 6148-6152); gene targeting in embryonic stem cells (Thompson, et al, 1989, Cell 56, 313-321); electroporation of embryos (Lo, 1983, Mol. Cell. Biol.
  • transgenic animal clones containing a one or more component whose association results in the formation of a FRMS transgene, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal or adult cells induced to quiescence (Campbell, et al, 1996, Nature 380, 64-66; Wilmut, et al, Nature 385, 810-813).
  • the present invention provides for transgenic animals that carry a transgene of one or more component whose association results in the formation of a FRMS in all their cells, as well as animals that carry the transgene in some, but not all their cells, i.e., mosaic animals.
  • the transgene may be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail tandems.
  • the transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko, et al, 1992, Proc. Natl. Acad. Sci. USA 89, 6232-6236).
  • gene targeting is prefened. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene.
  • the transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene encoding one or more component whose association results in the formation of a FRMS in only that cell type, by following, for example, the teaching of Gu, et al. (Gu, et al, 1994, Science 265, 103-106).
  • the regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.
  • the expression of the recombinant component whose association results in the formation of a FRMS gene may be assayed utilizing standard techniques.
  • Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place.
  • the level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques that include but are not limited to Northern blot analysis of tissue samples obtained from the ammal, in situ hybridization analysis, and RT-PCR (reverse transcriptase PCR). Samples of the component gene-expressing tissue, may also be evaluated immunocytochemically using antibodies specific for the component transgene product.
  • the invention encompasses the use of a transgenic mouse for the development of model system which allows screening of a test vaccines intended as vaccines for a species other than mouse.
  • the test vaccine is a vaccine which is intended for a human.
  • the transgenic mouse model of the invention encompasses a mouse which is constructed to express the host cell receptors and/or co-receptors of another species for a virus which is not native to a mouse. Such mice are advantageous for the analysis of virus neutralization, since the effect of neutralizing antibodies directed to the host cell receptors is eliminated. These mice provide a model system for viral tolerance.
  • a transgenic mouse may be constructed or used which expresses human host cell receptor(s) for a virus capable of infecting a human (such as HTV).
  • vaccine studies utilize transgenic mice expressing human CD4 and CCR5 co-receptor under the control of CD4 regulatory elements which restrict co-expression to thymocytes and T helper lymphocytes (Killeen et al., 1993, EMBO J., 12:1547-53). These mice are used in order to allow for the analysis of virus neutralization without the confounding effect of neutralizing antibodies directed to CD4 or CCR5.
  • the immune response mimics that in humans; immunogenic epitopes are restricted to envelope and to HTV-dependent conformations of CD4 and co- receptor.
  • the present invention provides a novel use as a system for the analysis of HIV vaccines.
  • the transgenes function only to provide tolerance to the human CD4 and CCR5 components of the vaccine.
  • transgenic mice are immunized one or more times with the FRMS of the invention.
  • control immunogens may be used to vaccinate other mice which serve as a control.
  • the FRMS immunogen may be in any of the forms described herein including in cell lysate, in solution, in a cross-linked structure, isolated, purified, etc.
  • the FRMS immunogen may also be introduced to the mouse in a vaccine formulation.
  • sera or antibodies produced from mice immunized the FRMS or control immunogens are collected and assayed for the ability to neutralized PI virus. Serum is collected at an appropriate time following immunization to allow for the production of an immune response in the mouse. Such times are well known in the art.
  • sera is obtained 2 weeks following each immunization.
  • sera or antibodies are tested for the ability to neutralize two, three or four primary isolates of the virus. More preferably, sera or antibodies are tested for the ability to neutralize four, six, eight primary isolates of the virus. Most preferably, sera or antibodies are tested for the ability to neutralize 10-15, 15-25, or more primary isolates of the virus.
  • Neutralization of a primary isolate may be assayed by methods known in the art including those presented herein. In one embodiment, neutralization is determined by the inhibition of infectivity associated with incubating the test antibody with a sample of the virus to be used in infection. An antibody which inhibits (e.g. decreases or blocks) viral infection, is indicative of a neutralizing antibody.
  • sera or antibodies are tested for the ability to inhibit syncytia formation or to inhibit infection by cell-free virus and assess the effects of the compound on cell proliferation and viability.
  • the test antibody is a monoclonal antibody.
  • the test antibody is a human monoclonal antibody produced in response to a FRMS immunogen.
  • a virus neutralization assay is performed on more than one primary isolates.
  • virus neutralization assay are performed on 2-5, 5-10, 10-15 primary isolates. In a more prefened embodiment, neutralization assay are performed on 15-20, 20-30, or 30 or more primary isolates. In another prefened embodiment, the primary isolates assayed are from more than one viral clade.
  • Neutralization may characterized in terms of percent neutralization of a number of primary isolates. Generally, in this embodiment, a single assay is used to assess antibody neutralization. In one embodiment, an antibody of the invention neutralizes 30- 40%, 40-50%), or 50-60% of the primary isolates of the virus. In a prefened embodiment, an antibody of the invention neutralizes 60-75%, 70-85%, or 80-90% of the primary isolates of the virus. In a most prefened embodiment, an antibody of the invention neutralizes 90- 95%, 95-98%, or 99-100% of the primary isolates of the virus. In prefened embodiments, when mAb are tested for neutralization of primary isolates, neutralization is expressed as the number of foci in the presence of mAb (or hybridoma supernatant) relative to the number in the presence of medium alone.
  • Transgenic mice (hu CD4+, hu CCR5+, mouse CD4+) are immunized with an HIV FRMS immunogen (cross-linked COS-env co-cultured with U87-CD4-CCR5 cells) or with cell controls (U87-CD4-CCR5 cells alone or cocultured with mock-transfected COS cells). Sensitivity of the homologous 168P virus to neutralization by vaccine sera is determined with U87-CD4 cells expressing either CCR5 or CXCR4 co-receptor (see, LaCasse, et al., 1998, Science 72:2491; Follis, K.E., et al.,1998, Journal of Virology 72:7603).
  • HIV primary isolates may include but are not limited to 92US657, 92US660, 92TH014, 89.6, 320NSI, 320SI, SHTV89.6P, 168P, 92RW023, 92UG031, 92UG037, 92RW008, 93TN101, 93IN999, 93IN905, 93IN904, 92UG035, 92UG021, 92UG024, 92UG046, 92TH023, 92TH024, 93TH051, and 93TH053.
  • an antibody produced to an HTV FRMS by the methods of the invention is capable of neutralization of 60-70%, 70-80%, 80-85% of such primary isolates of HIV.
  • an antibody produced to an HTV FRMS is capable of neutralization of 80-90%, 90-95%, or 95-99% of such primary isolates of HTV.
  • an antibody produced to an HIV FRMS is capable of neutralization of 100% of such primary isolates of HIV.
  • primary isolates of HTV may include one or more isolates of clade A, B, C, D, E, F, G, H, or I. In other embodiments, primary isolates of HTV may include one or more isolates an M-group, O-group, or N-group.
  • neutralization activity can be demonstrated as antibody-mediated by methods known in the art. For example, sera can be adsorbed to a solid support containing Protein-A and Protein-G. In the case that an antibody is responsible for the virus neutralization activity of the sera, sera depleted of Protein-A and Protein-G binding-proteins will be expected to contain little or no virus neutralization activity, while eluate from the Protein-A and Protein-G solid support will be expected to contain virus neutralization activity.
  • the present invention provides a method of screening a molecular structure for vaccine efficacy comprising immunizing a transgenic non-human mammal with the molecular structure, wherein said transgenic non-human mammal expresses from one or more transgenes both human CD4 and a co-receptor for HTV, and detecting any neutralizing antibodies to HIV that are produced by said mammal.
  • the invention also provides a method of screening a molecular structure for vaccine efficacy comprising immunizing a transgenic non-human mammal with the molecular structure, wherein said transgenic non-human mammal expresses from one or more transgenes said one or more host cellular membrane proteins; and detecting any neutralizing antibodies to said virus that are produced by said mammal.
  • Immunopotency of the one or more immunogens of the invention can be determined by monitoring the immune response of test animals following immunization with the FRMS by use of any immunoassay known in the art. Generation of a humoral (antibody) response and/or cell-mediated immunity, may be taken as an indication of an immune response.
  • Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects.
  • methods of introduction of the vaccine may include oral, intracerebral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal or any other standard routes of immunization.
  • the immune response of the test subjects can be analyzed by various approaches such as: the reactivity of the resultant immune serum to the immunogen of the invention, as assayed by known techniques, e.g., enzyme linked immunosorbent assay (ELISA), immunoblots, radioimmune assays (RIA) radioimmunoprecipitations, etc.
  • ELISA enzyme linked immunosorbent assay
  • RIA radioimmune assays
  • protection of immunized hosts from infection by the pathogen and/or attenuation of symptoms due to infection by the pathogen in immunized hosts can serve as evidence of vaccine efficacy.
  • the vaccine of the invention may be tested in rabbits for the ability to induce an antibody response to the FRMS immunogen.
  • Male specific-pathogen-free (SPF) young adult New Zealand White rabbits may be used.
  • the test group each receives a fixed concentration of the vaccine.
  • a control group receives an injection of 1 mM Tris-HCl pH 9.0 without the FRMS immunogen.
  • Blood samples may be drawn from the rabbits every one or two weeks, and serum analyzed for antibodies to FRMS.
  • the presence of antibodies specific for the immunogen may be assayed, e ⁇ g., using an ELISA.
  • animal testing of viral vaccine effacy is by use of a transgenic mouse model as described herein in Section 5.7.1.
  • the invention also provides methods for optimizing and quantitating vaccines comprising the subject FRMS.
  • the subject complexes are prepared using autologous cells negating reactivity toward host cellular components.
  • Vaccine compositions comprising complexes prepared using non-autologous cells, however, can be assessed using transgenic animals genetically engineered to be tolerant to the host cellular components of the complexes. Using these transgenic animals it is possible to determine whether the success achieved by vaccinating with the fusion-complexes of the subject invention is due to novel fusion-competent epitopes presented by the complexes.
  • the FRMS result from the interaction of HTV(168P) viral envelope protein and the human proteins CD4 and CCR5.
  • transgenic mice genetically engineered to be tolerant to the human components of the vaccine.
  • Mice expressing both the human CD4 receptor and the human CCR5 co-receptor were used to evaluate the complex and demonstrate that the neutralizing antibody generated was to immunologic epitopes restricted to envelope protein or HIV-dependent conformations of CD4 and co-receptor. It is noted that these transgenic mice were originally used as a mouse model for HTV infection. Utilizing transgenic animals to screen vaccine immunogens is a novel use of these mice. Transgenic mice exhibiting tolerance to host portions of vaccines can be used to optimize vaccine components, test variants and evaluate adjuvants.
  • transgenic animals other than transgenic mice can be used to screen candidate vaccines.
  • the invention provides a method of screening a molecular structure for vaccine efficacy comprising immunizing a transgenic non-human mammal with a molecular structure comprising an epitope formed as a result of association of (a) an envelope protein of an enveloped virus, with (b) one or more cellular membrane proteins, which envelope protein and cellular membrane proteins are necessary and sufficient under suitable conditions for fusion of said envelope of the virus with a cell membrane containing said cellular membrane proteins, wherein said transgenic non-human mammal expresses from one or more transgenes said one or more host cellular membrane proteins; and detecting any neutralizing antibodies to said virus that are produced by said mammal.
  • the molecular structure is isolated.
  • the invention provides a method of screening a molecular structure for vaccine efficacy comprising immunizing a transgenic non-human mammal with a molecular structure comprising an epitope formed as a result of association of (a) an HIV envelope protein, or a mutant thereof that assembles into the viral envelope; with (b) human CD4 and a co-receptor for HTV fusion, wherein said transgenic non-human mammal expresses from one or more transgenes both human CD4 and a co-receptor for HTV, and detecting any neutralizing antibodies to HTV that are produced by said mammal.
  • the mammal is a mouse.
  • the molecular structure is isolated.
  • the antibodies generated by the vaccine formulations of the present invention antibodies can be used in methods known in the art.
  • the antibodies generated against the FRMS or vaccine immunogen by immunization with the FRMS of the present invention also have potential uses such as diagnostic immunoassays, passive immunotherapy, viral decontamination, anti- viral treatment and prevention and generation of antiidiotypic antibodies.
  • the subject invention also encompasses antibodies that are elicited by the novel epitopes of the FRMS of the subject invention contain antibodies useful as reference standards and components in diagnostic assays and kits.
  • mAb to the FRMS of the subject invention can be used as reference standards, diagnostic agents for in vitro and in vivo bioassays and as markers for critical determinants in binding and fusion.
  • the mAb of the invention are useful in determining the amount of FRMS produced in each batch or lot.
  • the mAb may be used to determine the amount to lot-to-lot variation (e.g.,
  • labeled FRMS may be used, by way of a competition assay with the test FRMS for binding a mAb specific for the FRMS.
  • Similar assays may be used to determine the antibody titer of a sample of serum from a subject.
  • a sample of serum from a subject is taken at a time following administration of the vaccine of the invention.
  • the sample serum is then tested for ability to neutralize virus.
  • the serum may also be tested for the ability to bind to the immunogen FRMS, or to compete with a neutralizing mAb for binding to the immunogen FRMS.
  • the inability or weak ability of the serum sample to neutralize virus or bind FRMS provides an indication that booster vaccinations with the FRMS immunogen are desired for the subject.
  • the present invention provides a method for monitoring the production of antibody to the molecular structure in a subject previously administered an amount of the molecular structure comprising isolating from said subject a sample comprising serum; and detecting the presence of any antibodies to the molecular structure in said serum.
  • detecting is carried out by a method comprising performing a competitive immunoassay with labeled antibody to the molecular structure.
  • polyclonal sera or monoclonal antibodies can be administered to individuals for purposes of treatment or prevention of viral infection and its sequences.
  • such antibody can be administered for purposes post-exposure prophylaxis or to prevent maternal transfer of virus to the neonate by way of passive immunization.
  • Humanized mAb of the invention can be used in protection against maternal-infant virus transmission or in post-exposure prophylaxis or treatment.
  • MAb of the present invention are also useful in passive immunization studies in a hu-PBL-scid mouse model of HTV infection and in SHTV studies in rhesus macaques. Accordingly, the present invention provides a method for treating or preventing infection by HTV in a human fetus comprising administering to a pregnant human containing said fetus an amount of the monoclonal antibody effective to treat or prevent infection by HTV in said fetus.
  • Production of mAb to the FRMS of the subject invention can be used to further delineate the biochemical and immunochemical pathway to infection, and define critical epitopes for PI virus neutralization.
  • Monoclonal antibodies (mAb) generated to the FRMS of the subject invention can be used to dissect the biochemical basis for binding and entry, and the immunochemical basis for primary isolate virus neutralization.
  • immunogens should be chosen for MAb development that excel in immunogenicity studies in vaccination models, are potent and elicit a broad range of primary isolate virus neutralizing antibodies.
  • the antibodies of the present invention can also be used in the production of antiidiotypic antibody.
  • the antiidiotypic antibody can then in turn be used for immunization, in order to produce a subpopulation of antibodies that bind the initial antigen of the pathogenic microorganism (Jerne, 1974, Ann. Immunol. (Paris) 125c:373; Jerne, et al., 1982, EMBO J. 1:234).
  • mAb can also be used as an anti-viral agent in blood and blood products.
  • the present invention provides neutralizing antibodies that are useful as an additive for the decontamination of blood or blood products which are contaminated or suspected of being contaminated with a virus.
  • the mAb of the invention is useful as an additive to donor blood (e.g., blood within a blood bank) which is to be used in the treatment of a subject.
  • the mAb of the invention is useful as an additive to blood collection bags, gloves, blood sample collection containers, etc.
  • one or more mAb(s) of the invention are used to cleanse the birth canal prior to delivery of a child in order to prevent perinatal infection.
  • Effective amounts of the mAb of the invention for blood and blood-product additives include 1 ⁇ g/ml to lOmg/ml. As will be apparent to one skilled in the art, effective amounts will be influences by antibody affinity, additives, and formulations. Any amount may be used such that the effective amount is capable of inhibiting (e.g. reducing or preventing) viral infection.. In a prefened embodiment, a mixture of neutralizing mAb against a variety of viruses is used in decontamination. In a specific embodiment, an effective amount of a neutralizing mAb of the invention which is immunospecific for HTV is added to a sample of human blood before such blood is transfused into a recipient subject. In this embodiment, the HTV is neutralized by the mAb.
  • the present invention provides a sample of mammalian blood, to which an amount of the antibody has been added effective to inhibit or decrease infection by the virus.
  • the present invention provides a sample of human blood, to which an amount of the antibody has been added effective to inhibit or decrease infection by HIV.
  • the present invention also provides a method of inhibiting infection by a virus in a sample of blood comprising contacting said sample of blood with an amount of the monoclonal antibody effective to inhibit infection by said virus.
  • the present invention provides a method of inhibiting infection by HTV in a sample of human blood comprising contacting said sample of human blood with an amount of the monoclonal antibody effective to inhibit infection by HTV.
  • the neutralizing antibodies of the invention are also useful in decontaminating any object exposed to the virus to which the antibody is directed.
  • Objects which may be decontaminated with the mAb of the invention include but are not limited to surgical and dental tools (such as drills, picks, scalpels, etc).
  • a mixture of neutralizing mAb against a variety of viruses is used in decontamination.
  • objects which are not readily disposable e.g. , computer aided tools, robotic aided tools, specialized tools, etc.
  • Effective amounts of the mAb of the invention for decontamination include 1 ⁇ g/ml to lOmg/ml.
  • the present invention provides a method of decontaminating surgical or dental tools comprising contacting said tools with an amount of the monoclonal antibody effective to inhibit infection by said virus.
  • the present invention provides a method of decontaminating surgical or dental tools comprising contacting said tools with an amount of the monoclonal antibody effective to inhibit infection by HTV.
  • antibodies directed to an FRMS may be used to screen molecules which comprise an epitope recognized by the antibody.
  • a mAb oft he invention can be used to screen small molecules for the presence of an antibody-recognized epitope.
  • binding of the mAb to the small molecules indicates the presence of such epitope on the small molecule.
  • Such small molecules in turn may be tested as potential immunogens or therapeutics.
  • the mAbs of the invention may be used to identify peptides which bind to the antibody (e.g., from a phage display library). Such peptides may be tested, for example, for immunogenicity (i.e. as mimetopes).
  • the mAb of the invention are also useful as an anti- viral agent in contraceptive or microbicide products.
  • the addition of one or more mAb of the invention to a contraceptive or microbicide product is particularly prefened for viruses which are known to be sexually transmitted.
  • the invention provides a contraceptive product comprising an effective amount of one or more neutralizing mAb(s) of the invention.
  • Contraceptive or microbicide products to which the mAb of the invention may be added include but are not limited to creams, foams, jellies, ointment, condoms, diaphragms, etc.
  • the contraceptive products may further comprise of spermicidal agent.
  • a mixture of neutralizing mAbs against a variety of viruses is used in the contraceptive product.
  • Effective amounts of the mAb of the invention for contraceptive or microbicide products include 1 ⁇ g/ml to lOmg/ml.
  • effective amounts will be influences by antibody affinity, additives and formulations. Any amount may be used such that the effective amount is capable of inhibiting (e.g. reducing or preventing) viral infection.
  • an effective amount is that which is capable of inhibiting infection upon exposure by sexual transmission of a virus.
  • the contraceptive or microbicide products comprises mAb of the invention immunospecific to HTV or other sexually transmitted virus. Accordingly, the present invention provides a contraceptive or microbicide in the form of a jelly, foam, cream, or ointment comprising an amount of the
  • SUBST/TUTESHEET(RULE 6) antibody of the invention effective to inhibit or decrease infection by the virus.
  • the present invention provides a contraceptive or microbicide in the form of a jelly, foam, cream, or ointment comprising an amount of the antibody of the ineffective to inhibit or decrease infection by HIV.
  • the present invention provides methods of eliciting production of anti- FRMS antibodies in a subject by the administration of a FRMS.
  • Any of the FRMS of the invention, and functionally active fragments, analogs, and derivatives thereof; nucleic acids encoding the FRMS of the invention, and functionally active fragments and derivatives thereof; as well as antibodies which immunospecifically bind to a FRMS may be used as therapeutic, (termed herein "Therapeutic").
  • compositions comprise a therapeutically effective amount of a Therapeutic, and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the Therapeutic is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • Water is a prefened carrier when the pharmaceutical composition is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like.
  • the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like.
  • the composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin.
  • Such compositions will contain a therapeutically effective amount of the Therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient.
  • the formulation should suit the mode of administration.
  • the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings.
  • compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
  • the Therapeutics of the invention can be formulated as neutral or salt forms.
  • Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
  • GENE THERAPY Gene therapy refers to therapy performed by the administration of a nucleic acid molecule to a subject.
  • the nucleic acid molecule(s) produces its encoded protein(s) and mediates a therapeutic effect by forming a FRMS in vivo.
  • a nucleic acid molecule comprising a sequence encoding one or more components whose association results in the FRMS of the invention or a functional derivative thereof, are administered to produce an immunological response to the FRMS, by way of gene therapy.
  • a nucleic acid or nucleic acids encoding a viral envelope protein of an envelope virus, a host cell receptor, and a host cell co-receptor or functional derivatives thereof are admimstered by way of gene therapy.
  • a viral envelope protein of an envelope virus administered by way of gene therapy. Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.
  • the Therapeutic comprises an HIV envelope protein and a human CD4 receptor, and a co-receptor (such as a chemokine receptor CCR5 or CXCR4) in a suitable host.
  • a co-receptor such as a chemokine receptor CCR5 or CXCR4
  • a nucleic acid molecule is used in which the HTV envelope protein coding sequence is delivered to a subject, which subject expresses native CD4 and a native co-receptor.
  • Delivery of the nucleic acid into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vector, or indirect, in which case, cells are first transformed with the nucleic acid in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo and ex vivo gene therapy.
  • the nucleic acid is directly administered in vivo, where it is expressed to produce the encoded product.
  • This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or other viral vector (see, U.S. Patent No.
  • a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide that disrupts endosomes, preventing lysosomal degradation of the nucleic acid.
  • the nucleic acid can be targeted in vivo for cell specific uptake and expression by targeting a specific receptor (see, e.g., International Patent Publications WO 92/06180 by Wu et al, WO 92/22635 by Wilson et al., WO 92/20316 by Findeis et al., WO 93/14188 by Clarke et al., and WO 93/20221 by Young).
  • the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935, Zijlstra et al., 1989, Nature 342:435-438).
  • a viral vector that contains a nucleic acid encoding a viral envelope protein, and host cellular membrane protein(s) are used.
  • Any of the viral vectors described in Section 5.1.2, may be used for gene therapy purposes.
  • a retroviral vector can be used (see Miller et al., 1993, Meth. Enzymol. 217:581-599). These retroviral vectors have been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA.
  • Other references illustrating the use of retroviral vectors in gene therapy include: Clowes et al, 1994, J. Clin. Invest.
  • Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, 1993, Cunent Opinion in Genetics and Development 3:499-503 present a review of adenovirus-based gene therapy.
  • Adeno-associated virus has also been proposed for use in gene therapy (Walsh et al., 1993, Proc. Soc. Exp. Biol. Med. 204:289-300).
  • Another approach to gene therapy involves transferring a gene into cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection.
  • Any method known in the art to transfer a gene into a cell may be used in connection with the gene therapy aspect of the invention, including but not limited to those described in Section 5.1.2.
  • the method of transfer includes the transfer of a selectable marker to the cells.
  • the cells are then placed under selection to isolate those cells that have taken up and are expressing the transfened gene. Those cells are then delivered to a patient.
  • the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection,
  • Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, 1993, Meth. Enzymol. 217:599-618, Cohen et al., 1993, Meth. Enzymol. 217:618-644, Cline, 1985, Pharmac. Ther.
  • 29:69-92 and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted.
  • the technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell, and is heritable and expressible by its cell progeny.
  • the resulting recombinant cells can be delivered to a patient by various methods known in the art.
  • epithelial cells are injected, e.g., subcutaneously.
  • recombinant skin cells may be applied as a skin graft onto the patient.
  • Recombinant blood cells e.g., hematopoietic stem or progenitor cells
  • the amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.
  • Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes, and blood cells, such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone manow, umbilical cord blood, peripheral blood, fetal liver, etc.
  • the cell used for gene therapy is autologous to the patient.
  • a nucleic acid molecule encoding the components whose association results in the formation of a FRMS is used.
  • the nucleic acid encodes an HIV viral envelope protein, human CD4 and a co-receptor (such as a chemokine receptor CCR5 or CXCR4).
  • the encoding nucleic acid molecule is/are introduced into the cells such that the gene or genes are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect.
  • stem or progenitor cells are used.
  • stem and/or progenitor cells which can be isolated and maintained in vitro can potentially be used in accordance with this embodiment of the present invention.
  • Such stem cells include but are not limited to hematopoietic stem cells (HSC), stem cells of epithelial tissues such as the skin and the lining of the gut, embryonic heart muscle cells, liver stem cells (International Patent Publication WO 94/08598), and neural stem cells (Stemple and Anderson, 1992, Cell 71:973-985).
  • the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region (see Section 5.1.2), such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.
  • the invention provides a method of treating or preventing infection by a virus in a subject comprising administering to the subject (a) a first nucleic acid encoding an envelope protein of an enveloped virus; and (b) a second nucleic acid encoding one or more cellular membrane proteins, which envelope protein and cellular membrane proteins are necessary and sufficient under suitable conditions for fusion of said envelope of the virus with a cell membrane containing said cellular membrane proteins, such that the envelope protein and cellular membrane proteins are expressed in the subject and neutralizing antibodies to the virus are produced.
  • the method wherein the first and second nucleic acids are the same.
  • the first and second nucleic acid are different nucleic acid vectors.
  • the envelope protein is en envelope protein of HTV
  • the cellular membrane proteins are CD4 and an HTV co-receptor.
  • the invention provides methods of treatment and prevention of viral infection and disease by administration to a subject in need of such treatment of a therapeutically or prophylactically effective amount of a Therapeutic of the invention.
  • the subject is preferably an animal, including, but not limited to, animals such as monkeys, cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.
  • the subject is a human not afflicted with HTV infection.
  • a Therapeutic of the invention e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the Therapeutic, receptor-mediated endocytosis (see, e.g., Wu et al., 1987, J. Biol. Chem. 262:4429-4432), construction of a Therapeutic nucleic acid as part of a retroviral or other vector, etc.
  • Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes.
  • the compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be admimstered together with other biologically active agents. Administration can be systemic or local.
  • Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.
  • compositions of the invention comprising antibody locally to the area in need of treatment; this may be achieved, for example and not by way of limitation, by topical application, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.
  • the pharmaceutical compositions of the invention is administered to an open wound of a human, which wound is suspected of being exposed to HTV.
  • the Therapeutic can be delivered in a vesicle, in particular a liposome (see, Langer, 1990, Science 249:1527-1533; Treat et al., 1989 in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365; Lopez-Berestein, Science., pp. 317-327; see generally Science.)
  • the Therapeutic can be delivered in a controlled release system.
  • a pump may be used (see Langer, supra; Sefton, 1987, CRC Crit. Ref. Biomed. Eng. 14:201; Buchwald et al, 1980, Surgery 88:507; Saudek et al., 1989, N. Engl. J. Med. 321 :574).
  • polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger et al., 1983, J.
  • a controlled release system can be placed in proximity of the therapeutic target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in Medical Applications of Controlled Release, 1984, supra, vol. 2, pp. 115-138).
  • compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labelled for treatment of an indicated condition.
  • the present invention provides assays to test the anti-HTV efficacy of antibodies directed to an HTV-FRMS.
  • the invention further provides methods to monitor FRMS vaccine efficacy in patients or subjects by assaying antibodies in a sample of sera derived from the patient or subject following vaccination
  • the Therapeutics of the invention are preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. Any in vitro or in vivo assay known in the art to measure viral infection or production can be used to test the efficacy of a Therapeutic of the invention.
  • a method of screening a preparation comprising a mAb for anti-HTV activity comprises assaying said preparation or fraction for the ability to inhibit HTV infection.
  • hematopoietic cells e.g., primary PBMCs, isolated macrophages, isolated CD4 + T cells or cultured H9 human T cells
  • HTV-l hematopoietic cells
  • titers known in the art to acutely infect cells in vitro such as 10 5 TCID 50 /ml.
  • appropriate amounts of the Therapeutic are added to the cell culture media.
  • Cultures are assayed 3 and 10 days after infection for HTV-l production by measuring levels of HTV antigen using an ELISA assay. Reduction in HIV antigen levels over levels observed in untreated controls indicates the Therapeutic is effective for treatment of HTV infection.
  • any commercially available HTV ELISA may be used as a comparative assay for pre- and post- treatment with the Therapeutic.
  • a reporter gene i.e., a gene the protein or RNA product of which is readily detected, such as, but not limited to, the gene for chloramphenicol acetyltransferase (CAT)
  • CAT chloramphenicol acetyltransferase
  • the resulting construct is then introduced by transfection, or any other method known in the art, into a cultured cell line, such as, but not limited to, the human CD4 + T cell line HUT 78.
  • HTV-l LTR After exposure of the transformed cells to the Therapeutic, transcription from the HTV-l LTR is determined by measurement of CAT activity using techniques which are routine in the art. Reduction in HTV-l LTR driven transcription demonstrates utility of the Therapeutic for treatment and/or prevention of HTV infection.
  • Infection is monitored by the appearance of STV p27 antigen in PBMCs.
  • Utility of the Therapeutic is characterized by normal weight gain, decrease in STV titer in PBMCs and an increase in CD4 + T cells.
  • a SHTV model is used in which an HTV env protein is constructed into the backbone of STV.
  • monkeys are immunized using a FRMS vaccine comprising cells expressing HTV env and cells expressing rhesus CD4 and CCR5 coreceptor. If adequate in vitro neutralization is obtained, then animals will be challenged with an infectious SHIV virus bearing a neutralization-sensitive HTV env.
  • monkeys are vaccinated with an immunogen comprising one or more FRMS and challenged with SHTV 89.6P primary isolate (see e.g., Montefiori et al., 1998, J Virol. 72:3427-31).
  • the utility of the Therapeutic can be determined in human subjects.
  • the efficacy of treatment with a Therapeutic can be assessed by measurement of various parameters of HTV infection and HIV associated disease.
  • the change in viral load can be determined by quantitative assays for plasma HIV-l RNA using quantitative RT-PCR (Van Gemen, B., et al., 1994, J. Virol. Methods 49:157-168; Chen, Y.H., et al., 1992, AIDS 6:533-539) or by assays for viral production from isolated PBMCs.
  • Viral production from PBMCs is determined by co-culturing PBMCs from the subject with non- infected PBL cells and subsequent measurement of HTV-l titers using an ELISA assay for p24 antigen levels (see e.g.,Wrin, T., et al., 1995, Science 69:39; Popovic, M., et al., 1984, Science 204:497-500).
  • Administration of the Therapeutic can also be evaluated by assessing changes in CD4 + T cell levels, body weight, or any other physical condition associated with HTV infection or AIDS or ADDS Related Complex (ARC).
  • kits comprising the fusion-competent protein complexes or antibodies generated by those complexes.
  • Kits including the subject complexes or antibodies can be used to analyze vaccine lots, conduct stability studies or develop vaccine release qualifications.
  • Antibodies and the complexes can also be used in diagnostic kits to detect the presence of antibody or virus in the host system.
  • antibodies or the subject complexes can be used as substrate or reagent in a kit providing a standard diagnostic enzyme-linked immunosorbent assay (ELISA) or competitive ELISA.
  • ELISA enzyme-linked immunosorbent assay
  • the invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the vaccine formulations of the invention.
  • a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the vaccine formulations of the invention.
  • Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
  • the invention provides a kit comprising in one or more containers a labeled monoclonal antibody to a molecular structure comprising an epitope formed as a result of association of (a) an envelope protein of an enveloped virus, with (b) one or more cellular membrane proteins, which envelope protein and cellular membrane proteins are necessary and sufficient under suitable conditions for fusion of said envelope of the virus with a cell membrane containing said cellular membrane proteins.
  • the invention provides a kit which further comprises in a separate container a molecular structure comprising an epitope formed as a result of association of (a) an envelope protein of an enveloped virus, with (b) one or more cellular membrane proteins, which envelope protein and cellular membrane proteins are necessary and sufficient under suitable conditions for fusion of said envelope of the virus with a cell membrane containing said cellular membrane proteins.
  • the invention provides a kit comprising in one or more containers a labeled monoclonal antibody to a molecular structure comprising an epitope formed as a result of association of (a) an HIV envelope protein, or a mutant thereof that assembles into the viral envelope; with (b) human CD4 and a co-receptor for HTV fusion.
  • the invention provides a kit which further comprises in a separate container an epitope formed as a result of association of (a) an HTV envelope protein, or a mutant thereof that assembles into the viral envelope; with (b) human CD4 and a co-receptor for HIV fusion.
  • the invention provides a kit comprising in one or more containers, a molecular structure comprising an epitope formed as a result of association of (a) an envelope protein of an enveloped virus, with (b) one or more cellular membrane proteins, which envelope protein and cellular membrane proteins are necessary and sufficient under suitable conditions for fusion of said envelope of the virus with a cell membrane containing said cellular membrane proteins.
  • the molecular structure is isolated.
  • the invention provides a kit which further comprises a pharmaceutically acceptable carrier, and wherein said molecular structure is present in an immunological amount.
  • the invention provides a kit comprising in one or more containers (a) a first nucleic acid encoding an envelope protein of an enveloped virus; and (b) a second nucleic acid encoding one or more cellular membrane proteins, which envelope protein and cellular membrane proteins are necessary and sufficient under suitable conditions for fusion of said envelope of the virus with a cell membrane containing said cellular membrane proteins, such that the envelope protein and cellular membrane proteins are expressed in the subject and neutralizing antibodies to the virus are produced.
  • the inventors of the present invention have made the surprising discovery that the ability to neutralize PI viruses is related to the presentation of functioning envelope protein in active infection, as compared to the static, non-functioning presentation of the envelope protein in rgpl20 vaccines.
  • the HIV envelope protein orchestrates a complex series of protein-protein interactions and structural changes that ultimately results in fusion of the virus and cell membranes, and infection of the cell.
  • the envelope protein Upon binding to CD4, the envelope protein undergoes conformational change that facilitates subsequent interaction with one of several co-receptor molecules, predominantly the CC chemokine receptor 5 (CCR5) or the CXC chemokine receptor 4 (CXCR4) (Berger, E.A., 1997, AIDS 11 (suppl A), S3; Moore, J.P., et al., 1997, Cunent Opinions in Immunology 9:551; Doranz, B.J., et al., 1997, Immunology Research 16:15).
  • CCR5 CC chemokine receptor 5
  • CXCR4 CXC chemokine receptor 4
  • HTV vaccine immunogens were developed by the methods of the invention that explicitly incorporate these functional intermediate structures.
  • Example 1 Broad Primary Isolate Neutralization from HTV-FRMS Immunogen
  • HTV vaccine immunogens were generated that capture the transient structures that arise during HIV binding and fusion.
  • formaldehyde-fixed whole cell vaccines elicited antibodies capable of neutralizing infectivity of 23 of 24 primary HTV isolates from diverse geographic locations and genetic clades A-E.
  • Development of these fusion-dependent immunogens provide clinically important and broadly effective HTV vaccines.
  • the HTV envelope protein orchestrates a complex series of protein-protein interactions and structural changes that ultimately results in fusion of the virus and cell membranes, and infection of the cell.
  • the envelope protein upon binding to CD4, the envelope protein undergoes conformational change that facilitates subsequent interaction with one of several co-receptor molecules, predominantly the CC chemokine receptor 5 (CCR5) or the CXC chemokine receptor 4 (CXCR4) (Reviewed in Berger, E.A., 1997, AIDS ll(suppl A), S3; Moore, J.P., et al., 1997, Cunent Opinions in Immunology 9:551; Doranz, B.J., et al., 1997, Immunology Research 16:15).
  • CCR5 CC chemokine receptor 5
  • CXCR4 CXC chemokine receptor 4
  • envelope protein function is the ability to mediate cell-cell fusion.
  • envelope protein When cells expressing envelope protein are cocultured with cells expressing CD4 and co-receptor, multinucleated syncytia form over the course of 6-24 hr. hi the instant example, the process of binding and fusion was captured in progress by formaldehyde- crosslinking prior to extensive syncytium-formation.
  • the functioning envelope protein was derived from a T- lymphocytropic PI virus obtained from the Amsterdam Cohort (ACH168.10; 168P).
  • the molecularly cloned envelope gene of ACH168.10 was isolated by PCR using the pCR3.1- Uni plasmid (Invitrogen) (Tersmette, M., et al., 1989, Journal of Virology 63:2118; Wrin, T., et al., 1995, Science 69:39; LaCasse, R.A., et al., 1998, Journal of Virology 72:2491).
  • the molecularly cloned envelope protein as well as the parental syncytium-inducing(SI) virus, utilizes both CCR5 and CXCR4 co-receptors.
  • Cos-7 cells were transfected to express the envelope protein (COS-env) and subsequently cocultured with human U87 glioma cells that express CD4 and CCR5 co- receptor (U87-CD4-CCR5).
  • the functional 168P (168P23) envelope gene was transfected into COS-7 cells (American Type Culture Collection, Manassus, VA) by calcium phosphate precipitation (20 ⁇ g DNA/10 6 cells/10 cm culture dish) by methods known in the art (see e.g., Jordan, M., et al., 1996, Nucleic Acids Research 24:596).
  • Transiently-expressing COS- 7 cells were harvested 2 days later using 0.5 mM EDTA in phosphate-buffered saline (PBS), and U87-CD4-CCR5 fusion partners (Hill, CM., et al., 1997, Journal of Virology 71 :6296) were prepared using 0.1 mM EDTA in PBS.
  • Cocultures were initiated by mixing the two cell types (1.5xl0 6 cells each) in 10 cm culture dishes. The time course of cell-cell fusion was monitored microscopically and by immunochemical staining (HTVIG) in parallel cocultures (LaCasse, R.A., et al., 1998, Science 72:2491). Cocultures were typically harvested by formaldehyde fixation at 4-5 hrs, when little or no overt syncytium formation was evident.
  • HTVIG immunochemical staining
  • Cells were subsequently scraped, washed twice with PBS, resuspended at a nominal density of 3x10 6 cells/0.1 ml in PBS containing 10% DMSO, and frozen at -80° for storage or used immediately as immunogens, as described herein below.
  • ahu CCR5 transgenic mouse Construction of a CD4 targeted-deletion and hu CD4 transgenic mouse has been described (Killeen, N., et al., 1993, EMBO Journal 12:1547).
  • the design of ahu CCR5 transgenic mouse is summarized as follows: a 1.15 kb hu CCR5 cDNA was molecularly cloned into an engineered Sail site in exon 2 of a murine CD4 expression cassette (construct c in (Sawada, et al., 1994, Cell 77:917).
  • This minigene contained the murine CD4 enhancer, the CD4 promoter, the first (noncoding) exon, and intron 1 with an internal deletion that eliminated the CD4 silencer.
  • Transgenic founders were identified by flow cytometry using a mAb by methods known in the art. These animals were bred to hu CD4 expressing transgenic mice to yield progeny expressing hu CD4, hu CCR5, and mouse CD4. Pups were screened for expression of hu CD4, hu CCR5, and mouse CD4 by flow cytometry using a Coulter EPICS ELITE flow cytometer. The following antibody reagents were used: mouse ⁇ -human CD4/CyChrome (Pharmingen), mouse ⁇ -human CCR5 MAB 180 (R&D Systems) with goat ⁇ -mouse Ig/FITC (Caltag), and rat ⁇ -mouse CD4 L3T4/PE.
  • mice expressing hu CD4, hu CCR5, and mouse CD4 were immunized with either FRMS immunogen or with cell controls (U87-CD4-CCR5 cells, alone or cocultured with mock-transfected COS cells).
  • Vaccines comprised formaldehyde- fixed whole cells (3x10 6 cells/0.1 ml) formulated with an equal volume of Ribi adjuvant (R- 700; reconstituted in half the recommended volume of PBS); in some experiments, the initial immunization was with adjuvant containing cell wall material (R-730). Mice received 0.05 ml vaccine in four subcutaneous sites.
  • Booster immunizations were at three week intervals, and mice were bled at 10-28 days post-immunizations from the tail. Serum antibodies directed to gpl 20 were quantitated by gpl 20 ELISA as per methods known in the art (see, Moore, J., et al., 1989, AIDS 3:155).
  • Sensitivity of the homologous 168P virus to neutralization by vaccine sera was determined with U87-CD4 cells expressing either CCR5 or CXCR4 co-receptor.
  • This PI virus neutralization assay has been validated relative to standard neutralization assay in PBL culture (LaCasse, R.A., et al., 1998, Science 72:2491; Follis, K.E., et al., 1998, Journal of Virology 72:7603) and was determined to perform well in the presence of mouse serum. All sera were heat-inactivated prior to use in neutralization assays.
  • Sera were tested for neutralization of 168P using U87- CD4 cells expressing either CXCR4 (black symbols) or CCR5 (white symbols). Data represent averages of three to six neutralization assays using serum obtained 2 weeks following second and third immumzation.
  • results of virus neutralization assays indicated that no inhibition of infectivity was observed in sera from mice immunized with cell controls, indicating that the transgenic mice were in fact tolerant to hu CD4 and CCR5 and that other adventitious cellular reactivities did not interfere with the virus infectivity assay (Fig 1).
  • Sera from mice immunized with FRMS immunogens neutralized the homologous 168P PI virus.
  • Neutralization activity was further demonstrated to be antibody-mediated and as such activity could be adsorbed to, and subsequently eluted from, a solid support containing Protein-A and Protein-G .
  • CXCR4 co-receptor may substitute for CCR5
  • SUBSTITUTE SHEET (RULE 2 ⁇ the CCR5 component of the vaccine. Further, the CXCR4 co-receptor may substitute for CCR5.
  • Fusion-Incompetent Immunogens The role of fusion-dependent determinants in the induction of PI virus neutralization was examined. Fusion-incompetent (FI) immunogens - cocultures that express env but do not undergo cell-cell fusion. These include COS-env cocultured with U87 cells (no CD4 or CCR5 co-receptor), COS-env cocultured with U87-CD4 cells, and COS-env cells to which soluble CD4 (sCD4) was complexed.
  • FI Fusion-incompetent immunogens - cocultures that express env but do not undergo cell-cell fusion. These include COS-env cocultured with U87 cells (no CD4 or CCR5 co-receptor), COS-env cocultured with U87-CD4 cells, and COS-env cells to which soluble CD4 (sCD4) was complexed.
  • envelope- expressing cultures were incubated with sCD4 (Berger, E.A., et al., 1988, Proceedings of the National Academy of Sciences USA 85:2357) (5 ⁇ g/ml; 1 hr at 37°) and subsequently washed to remove unbound sCD4. All FI immunogens were fixed with formaldehyde as above. An additional FI immunogen comprised COS-env and U87-CD4-CCR5 cells that were separately fixed with formaldehyde prior to mixing during the formulation of the vaccine.
  • FI immunogens were unable to elicit significant neutralization of the homologous PI virus (Fig 2 A). Specifically, PI 68 was neutralized by FC, but not FI immunogens.
  • PBLs human primary blood lymphocytes
  • FI immunogens Neutralization of the homologous 168P PI virus in human PBL culture by FC, but not FI immunogens was also demonstrated.
  • lymphocytes were isolated, stimulated with phytohemagglutinin, and grown in the presence of interleukin-2; neutralization was determined as described herein.
  • HTV p24 antigen was determined after 5 days of culture by ELISA (Coulter Corporation) and values were normalized to the virus control (36 ng/ml). * indicates p24 antigen levels below the limit of detection at the dilution
  • FC vaccine sera were shown not to inhibit infectivity of pseudotyped HIV virions bearing an amphotropic murine leukemia virus (MLV) envelope protein (Envelope-defective HTV NL4-3-Luc-R " E " pro virus was pseudotyped using amphotropic MLV envelope protein (Deng, H., et al., 1996, Nature 381:661). Further, FC HIV (MLV) envelope protein (Envelope-defective HTV NL4-3-Luc-R " E " pro virus was pseudotyped using amphotropic MLV envelope protein (Deng, H., et al., 1996, Nature 381:661). Further, FC VMV envelope-defective HTV NL4-3-Luc-R " E " pro virus was pseudotyped using amphotropic MLV envelope protein (Deng, H., et al., 1996, Nature 381:661).
  • FC vaccine serum did not neutralize pseudotyped HTV 15 virions bearing amphotropic MLV envelope protein or primary STVmac251.
  • HIV bearing an amphotropic MLV envelope protein (ampho MLV pseudotype) was used in neutralization sensitivity using pooled FC and FI antisera determined in U87-CD4-CXCR4 . cells.
  • Primary isolate STVmac251 neutralization was determined in U87-CD4-CCR5 cells. Symbols are as defined in Fig 2 FC immunogen (black squares) and FI immunogen (Cos- 20 env + U87 cells, black circles).
  • FI vaccines were able to elicit neutralization of a related laboratory-adapted isolate of HTV, the T-cell line adapted
  • Infectious proviruses ACH320.2A.1.2 (320SI) and ACH320.2A.2.1 (320NSI) were obtained through the NTBSC (UK) ATDS Reagent Program).
  • HTV89.6 Cold, R., et al., 1992, Journal of Virology 66:7517
  • SHTV89.6, and SHIV89.6P were also used.
  • FC sera elicited by a functioning clade B envelope protein were able to neutralize 23 of 24 PI viruses tested - monocytropic/NSI and T- lymphocytropic/SI viruses from North America/Europe (clade B), Africa (clades A and D), Thailand (clades B and E), and India (clade C).
  • Vaccine groups and symbols are as defined in Fig 2; sera were pooled for this assay.
  • FC immunogens of the invention may target primarily viral determinants.
  • FI sera were uniformly unable to neutralize these heterologous PI viruses.
  • the broad and uniform neutralization of diverse PI viruses by the FRMS immunogens suggests that the critical determinants presented by FRMS immunogens (such as FC immunogens) are highly conserved, and may be intimately tied to the basic functioning of the envelope protein in binding and fusion.
  • FC vaccines In order to more precisely define the molecular target for PI virus neutralization by FC vaccines, neutralizing antibodies were attempted to be removed from FC vaccine sera on incubation with envelope protein expressed on the surface of transfected COS cells. Accordingly, formaldehyde-fixed COS cells expressing 168P envelope protein were incubated with FC serum and the recovered serum was then tested for PI virus neutralization. FC vaccine serum was sequentially adsorbed four times with approximately 10 6 formaldehyde-fixed COS cells expressing 168P envelope. Incubations were for 1 hr at 4° with rocking. Controls included prebleed serum and formaldehyde-fixed mock- transfected COS cells. Adsorption of bulk anti-gpl20 antibody was momtored by gpl20 ELISA.
  • FC vaccine serum was removed by incubation with envelope-expressing cells, but only minimally reduced by incubation with COS cell controls (Fig 6 and Fig 7). Specifically, FC vaccine serum was repeatedly incubated with formaldehyde-fixed COS-env or control COS cells and tested for residual neutralization of 168P using U87-CD4-CXCR4 cells. Serum obtained prior to FC immunization was similarly adsorbed.
  • hybridoma supernatants were made by the methods of the invention (using cross-linked COS-env + U87-CD4-CCR5 as an immunogen) were capable of neutralizing primary isolates. Briefly, hybridomas assayed for virus neutralization in the U87-CD4-CXCR4 cell assay as described above. Hybridoma supernatants were tested for the ability to neutralize two representative HIV clade B isolates (ACH168.10 (168P) and 92US657). Neutralization is expressed as the number of foci in the presence of hybridoma supernatant relative to the number in the presence of medium alone. Each point represents a selected hybridoma. As shown in Fig. 8, a majority of hybridomas were found to neutralize both PI viruses to 60-80% (0.4 - 0.2 fraction infectivity remaining, respectively) .
  • the FRMS immunogens of the invention are capable of eliciting neutralizing monoclonal antibodies against primary isolate virus. Taken together, this
  • SUBST/TUTESHEET(RULE2 ⁇ example illustrates that an appropriately-presented clade B envelope protein can elicit potent neutralization against most PI viruses from multiple HIV clades and suggest that broad vaccine protection may not require an unlimited number HIV serotypes.
  • the static forms of the envelope protein does not function as an effective immunogen
  • the present invention recognizes that the critical fusion-related epitopes are sufficiently represented on the static protein to allow binding.
  • the FRMS immunogens of the invention provide broad protection against a wide variety of viral serotypes and clades.
  • three classes of mutations of the envelope protein include, but are not limited to: (1) mutations that abrogate proteolytic cleavage of the gpl 60 precursor protein; (2) mutations that affect the N-terminal gp41 fusion peptide domain; and (3) mutations that alter the coiled-coil domain.
  • Mutations that abrogated proteolytic cleavage of the gpl 60 precursor proteins include certain mutations that altered the highly conserved K R-X-K/R-R site at the C-terminus of gpl20 prevent proteolytic cleavage of the gpl60 polyprotein and also abrogate fusogenicity (Freed, E.O., et al., 1989, J. Virol. 63:4670-5; Guo H.G., et al., 1990, Virology, 174:217-24; Bosch V., et al., 1990, J. Virol. 1990:2337-44; Dubay, J.W., et al., 1995, J. Virol., 69:4675-82).
  • Site-directed mutagenesis was used to introduce a documented cleavage site mutation into the 168P envelope protein (REKR to REKT).
  • the cleavage-defective 168P envelope protein gpl 60 was expressed on the cell surface but was unable to mediate cell-cell fusion or infection by pseudotyped HIV virions.
  • Mutations that affect the N-terminal gp41 fusion peptide domain include mutation of the hydrophobic N-terminal region of gp41 which region is believed to mediate fusion by inserting into the cell membrane and destablizing the lipid bilayer. Certain amino acids changes within this region render the envelope protein nonfusogenics synthetic peptides.
  • SUBST/TUTESHEET(RULE2 (gp41 : AVGIGVLFLGFLG..) by site-directed mutagenesis and the envelope proteins is tested for expression are fusogenicity. Incorporation of these mutations into pAbT4587- 168Penv allows facile generation of the cognate recombination vaccinia viruses of the invention.
  • Mutations that alter the coiled-coil regions include mutations that are within the highly conserved coiled-coil motif is found in fusion proteins of many virus families (Weissenhorn, W., et al., 1998, Proc. Natl. Acad. Sci. USA 95:6032-6), for example, V570R and Y586E of HTV.
  • changes are introduced into the 168P envelope gene and tested for expression and fusogenicity in cell assays before being
  • Fusion-competent immunogens were prepared by co-cultivating calcium phosphate-transfected COS-7 (American Type Culture Collection, Rockville, MD) cells
  • mice expressing both human CD4 and CCR5 co-receptor were immunized three times at 21 day intervals with cells prepared and collected as in Example
  • Virus neutralization assays using the homologous PI virus 168P were performed using both U87-CD4-CCR5 and -CXCR4 cells, and in some cases sera were analyzed after the second as well as the third immumzation. In all cases, results were concordant and are averaged in the data presented in Fig 9. Potent neutralization of the homologous 168P PI virus was consistently observed; neutralization levels of ⁇ 80% were typically obtained at a 1:100 dilution of mouse serum. Neutralization was observed using CXCR4, a co-receptor to which the animal had not been exposed.
  • Residual neutralization might arise from antibodies directed to CD4 and CCR5 were tolerance to the transgenes to be incomplete.
  • control vaccines comprising U87-CD4-CCR5 cells, alone or cocultured with mock-transfected COS cell, were tested. In three studies, no inhibition of viral infectivity was observed. These data confirm tolerance in these transgenic mice and validate the vaccination model. Specific immune responses appear limited to viral and perhaps virus-induced epitopes. Not only do these mice appear tolerant to human CD4 and CCR5, as would human vaccinees, but antibodies directed to other cellular proteins do not appear to interfere with viral infectivity in this assay.
  • T-lymphocytropic PI virus which is particularly refractory to neutralization by HTV-IG, CD4-Ig, and Residual sera remaining in Example 3 were used to test the sensitivity of this PI virus to fusion-competent and fusion-incompetent immunogens. Although limited to a starting 1:100 dilution of fusion-competent serum, this heterologous clade B isolate was clearly sensitive to neutralization. Of interest also was the failure of the fusion-incompetent sera (env and env + CD4) to neutralize the heterologous 320SI virus, in contrast to the partial neutralization seen against the homologous 168P virus. (Fig. 10)
  • Fusion-competent sera elicited by a functioning clade B envelope protein were able to neutralize 23 of 24 PI viruses tested-monocytropic/NSI and T-lymphocytropic/SI viruses from North America Europe (clade B), Africa (clades A and D), Thailand (clades B and E), and India (clade C).
  • PI viruses tested-monocytropic/NSI and T-lymphocytropic/SI viruses from North America Europe (clade B), Africa (clades A and D), Thailand (clades B and E), and India (clade C).
  • One isolate (92RW008) failed to attain >50% neutralization and two others (931N904 and 92UG024) showed limited neutralization above 50%.
  • Control sera were uniformly unable to neutralize these heterologous PI viruses, in keeping with the historic failure of rgpl20 immunogens.
  • the FRMS of the subject invention were tagged using a commercially available system to facilitate their isolation and purification.
  • the molecular engineering methods used to construct S-peptide tagged CD4, CCR5, CXCR4 and HTV envelope are parallel and will be described in detail only for CD4-Spep. Molecules were tagged with an
  • SUBSTITUTE SHEET (RULE 2 ⁇ > S-peptide at the C-terminal end of the CD4 molecule.
  • the S peptide-encoding sequence (lys-glu-thr-ala-ala-ala-lys- phe-glu-arg-gln-his-met-asp-ser) was inserted between the cytoplasmic C-terminal isoleucine and termination codon (TGA) of the CD4 cDNA expression plasmid (CD4-Spep) using a synthetic oligonucleotide and high fidelity XL PCR (PE Applied Biosystems).
  • COS-7 cells were transfected with CXCR4 and either CD4-Spep or native CD4 (in pcDNA3.1 expression vectors), and 2 days subsequently labeled at the cell surface with biotin (EZ-Link Sulfo-NHS-LC-Biotin; Pierce Chemical Co.). Lysates were prepared in 0.5% Triton X-100 with protease inhibitors.
  • CD4 molecules were purified either by 1) immunoprecipitation using MAb T4 (Coulter Corp., Hialeah, FL) and rabbit- ⁇ -mouse Ig antibody-loaded Protein A agarose, or 2) affinity purification using S-protein agarose.
  • Proteins were released by boiling in sodium dodecyl sulfate (SDS) sample buffer, resolved by 10% polyacrylamide-SDS gel electrophoresis, and transfened to nitrocellulose. Biotinylated proteins were detected by avidin-horseradish peroxidase (Pierce) and nickel-enhanced DAB substrate. S-protein agarose resulted in the specific purification of the 62kD CD4-Spep with yield and purity which surpassed that of ⁇ -CD4-antibody mediated immunoprecipitation.
  • SDS sodium dodecyl sulfate
  • COS-7 cells were transfected with CD4-Spep ( ⁇ CXCR4) and were subsequently harvested in 0.5% Triton X-100 lysis buffer (control), or subjected to ice-cold formaldehyde fixation prior to lysis.
  • CD4-Spep protein was purified by S-protein agarose, and analyzed by Western blot using S-protein HRP (Novagen, Inc.). Minimal loss of S-peptide binding (and/or recovery) was seen with 0.2% formaldehyde fixation for 1 hr; some recovery was lost with 2% formaldehyde in 1 hr and more at 3 hr. Intermediate reaction conditions (e.g. 0.2% formaldehyde for 1-2 hr) will allow for efficient isolation of effectively cross-linked complexes.
  • DTSSP is a homobifunctional N-hydroxysuccinimidyl ester that reacts, as formaldehyde, with primary amines. Because of its negative charge, DTSSP cannot penetrate or cross the cell membrane and thus, in contrast to formaldehyde, is expected to spare the cytoplasmic S-peptide tag. Also unlike formaldehyde, DTSSP cross-linking is reversible; an internal disulfide linkage can be cleaved to release cross-linked components.
  • COS-7 cells were transfected with 168P envelope or CD4-Spe ⁇ plasmids; envelope expressing cells as well as mock transfected cells were metabolically labeled in a 10 cm dish for 8 hr using 1 mCi total 35 S-methionine and cysteine. Envelope (or mock) and CD4-Spep expressing cells were then co-cultured for 4 hr to allow cell-cell interaction, and subjected to formaldehyde (0.2%, 1 hr on ice) or DTSSP (2 mM, 2X10 min on ice) cross-linking. Lysates were prepared and S-peptide containing complexes were isolated by S-protein agarose affinity chromatography. Formaldehyde cross-linked complexes were analyzed by 6% polyacrylamide
  • DTSSP cross-linked complexes were examined. S-protein affinity purified complexes resolved by 6% polyacrylarnide/SDS gel electrophoresis with or without prior treatment with 50 mM DTT were analyzed. Envelope-specific complexes were unable to be clearly resolved above those isolated from the mock + CD4-Spep control, with DTSSP cross-links intact. Little gpl20/gpl60 was detected. However, reversal of DTSSP cross-linking results in the specific release of gpl20 and gpl60 proteins. These data confirm that the formation of envelope-CD4 complexes observed using formaldehyde fixation, and highlight the power in the use of reversible cross-linking agents.
  • envelope protein As anticipated, a large amount of 168P envelope protein was isolable following co-culture with cells expressing CD4-Spep. A lesser, but significant, amount of envelope protein was also isolable following co-culture with cells expressing CD4 and CCR5-Spep. Contaminating envelope protein was not detectable from co-cultures with mock-transfected cells. Complexes were isolated from formaldehyde cross-linked fusion-competent co-cultures in similar experiments.
  • Example 7 Recombinant Vaccinia Viruses That Generate Fusion-Competent FRMS in Cell Culture or at the Site of Vaccination.
  • Other acceptable vaccine approaches to translate our invention into a practical formulation include the use of viral vectors.
  • coadministration of recombinant vaccinia viruses that express env and CD4/CCR5, respectively might drive cell-cell fusion in situ.
  • two recombinant vaccinia viruses-one expressing HTV 168P envelope protein (rV-168Penv) and the second expressing CD4 and CCR5 co-receptor (rV-CD4/CCR5) were constructed.
  • Co-cultures of cells infected with rV-168Penv and cells infected with rV-CD4/CCR5 were fusion-competent and yield multinucleate syncytia (Fig. 12).
  • rV-168Penv cells, rV-CD4/CCR5 cells, or cross-linked cocultured rV-168Penv and rV-CD4/CCR5 cells were used as FRMS to vaccinate transgenic mice, as described above.
  • Sera obtained from mice are vaccinated with cross-linked cocultured rV-168Penv and rV-CD4/CCR5 cells are capable of virus neutralization across a variety of clades of HTV indicating that the viral vectors may successfully be used in the methods of the invention in the formation of the FRMS.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne la génération de structures FRMS (Fusion-Related Molecular Structures) comprenant un ou plusieurs déterminants transitionnels concernés par la fusion. On peut construire des vaccins très efficaces et qui présentent les déterminants concernés par les fusions au système immunitaire qui engendre des anticorps uniques capables de neutraliser puissamment une large gamme d'isolats primaires, et ce, avec malgré des provenances mondiales même à partir de différentes clades virales phylogénétiques. L'invention concerne des procédés permettant de former, d'isoler et de purifier la FRMS ainsi que l'utilisation de telles FRMS dans une variété de compositions et procédés, et notamment comme immunogènes vaccinaux, comme agents diagnostics et comme agents thérapeutiques. L'invention concerne notamment des FRMS capables de mettre en évidence la neutralisation d'anticorps face à des pathogènes viraux et des isolats primaires d'un virus. Des anticorps dirigés contre les FRMS peuvent servir à l'étude du chemin moléculaire aboutissant à la fusion du virus avec la cellule hôte, et à l'identification de points d'un possible blocage à médiation d'anticorps survenant sur ce chemin. L'invention concerne enfin l'utilisation d'anticorps de l'invention comme agents antiviraux, comme additifs pour produits sanguins, comme agent d'immunisation passive pour additifs contraceptifs dans le traitement postexposition ou l'immunisation foetale.
PCT/US1999/017487 1998-08-03 1999-08-03 Prevention et traitement de pathologie virale Ceased WO2000008043A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1020017001483A KR20010085326A (ko) 1998-08-03 1999-08-03 바이러스 질환의 예방과 치료
IL14121199A IL141211A0 (en) 1998-08-03 1999-08-03 Prevention and treatment of viral disease
EP99945011A EP1102788A4 (fr) 1998-08-03 1999-08-03 Prevention et traitement de pathologie virale
CA002338983A CA2338983A1 (fr) 1998-08-03 1999-08-03 Prevention et traitement de pathologie virale
JP2000563676A JP2002522448A (ja) 1998-08-03 1999-08-03 ウイルス疾患の予防および治療
AU57715/99A AU5771599A (en) 1998-08-03 1999-08-03 Prevention and treatment of viral disease
BR9912732-6A BR9912732A (pt) 1998-08-03 1999-08-03 Estrutura molecular isolada, vìrus envelopadorecombinante, formilação de vacina, anticorpomonoclonal, anti-soro policlonal, geléia, espuma,creme ou unguento contraceptivo, amostras desangue de mamìfero e de humano, kit, linhagemcelular, processos de tratamento ou deprevenção de infecção por um vìrus em sujeito, detratamento ou de prevenção de infecção por hivem um humano, de inibição de infecção por um vìrusem uma amostra de sangue, de inibição de infecçãopor hiv em uma amostra de sangue humano, dedescontaminação de ferramentas cirúrgicas oudentais, de monitoração de produto de anticorpopara a estrutura molecular, de produção de umimunógeno para uso em uma vacina para otratamento ou a prevenção de infecção por umvìrus, e de produção de um imunólogeno para usoem uma vacina para o tratamento ou a prevençãode infecção por hiv, estrutura reticulada,anticorpo monoclonal para a estrutura, dedescontaminação de ferramentas cirúrgicas oudentais, processo de seleção de uma estruturamolecular para eficácia de vacina, mamìfero,complexo de proteìna isolado, formulação devacina, processos de imunização de um animal paraum vìrus, e de preparação de um complexo deproteìna, células fixadas, processos depurificação de um complexo de proteìna e detratamento de um hospedeiro que tem sidoexposto a um vìrus, ou de prevenção de infecçãode um hospedeiro pelo citado vìrus, e composição.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9510598P 1998-08-03 1998-08-03
US60/095,105 1998-08-03
US14180699P 1999-06-29 1999-06-29
US60/141,806 1999-06-29

Publications (3)

Publication Number Publication Date
WO2000008043A2 WO2000008043A2 (fr) 2000-02-17
WO2000008043A3 WO2000008043A3 (fr) 2000-05-11
WO2000008043A9 true WO2000008043A9 (fr) 2001-12-13

Family

ID=26789760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017487 Ceased WO2000008043A2 (fr) 1998-08-03 1999-08-03 Prevention et traitement de pathologie virale

Country Status (9)

Country Link
EP (1) EP1102788A4 (fr)
JP (1) JP2002522448A (fr)
KR (1) KR20010085326A (fr)
CN (1) CN1321165A (fr)
AU (1) AU5771599A (fr)
BR (1) BR9912732A (fr)
CA (1) CA2338983A1 (fr)
IL (1) IL141211A0 (fr)
WO (1) WO2000008043A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160546B2 (en) 1995-06-06 2007-01-09 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
US7501123B2 (en) 2004-03-12 2009-03-10 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1141314A2 (fr) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations
FR2789590B1 (fr) * 1999-02-15 2003-01-17 Inst Rech Developpement Ird Compositions immunogenes utilisables comme vaccins
EP1130089A1 (fr) * 2000-02-17 2001-09-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Composition comprenant des particules sous-virales cibles et fusions de virus enveloppés, et vaccin la contenant
EP1331942A4 (fr) 2000-09-22 2005-03-16 Univ Duke Immunogene contenant la proteine d'enveloppe du vih liee a un ligand
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
CA2431881C (fr) * 2001-01-05 2011-02-22 Aventis Pasteur Polypeptide induisant des anticorps neutralisant le vih
FR2819256B1 (fr) * 2001-01-05 2004-04-30 Aventis Pasteur Polypeptide induisant des anticorps neutralisant le vih
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
WO2021096829A1 (fr) 2019-11-11 2021-05-20 Vanderbilt University Anticorps monoclonaux humains dirigés contre le hantavirus et leurs procédés d'utilisation
US20230273209A1 (en) * 2020-10-09 2023-08-31 Helmholtz Zentrum München - Deutsches Forschungszentrum Für Gesundheit Und Umwelt Method for determining whether or not virus-neutralizing antibodies are present and in vitro method for screening compounds for their ability to neutralize a virus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000103A1 (fr) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Proteines d'enveloppe chimeriques pour le ciblage de virus
WO1993005147A1 (fr) * 1991-08-30 1993-03-18 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Particules defectives interferentes du vih avec un cd-env chimerique

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160546B2 (en) 1995-06-06 2007-01-09 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
US9598469B2 (en) 2001-07-05 2017-03-21 Novartis Vaccines And Diagnostics, Inc. HIV-1 south african subtype C env proteins
US7282364B2 (en) 2001-08-31 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US7501123B2 (en) 2004-03-12 2009-03-10 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10

Also Published As

Publication number Publication date
WO2000008043A3 (fr) 2000-05-11
EP1102788A2 (fr) 2001-05-30
KR20010085326A (ko) 2001-09-07
AU5771599A (en) 2000-02-28
EP1102788A4 (fr) 2002-08-28
IL141211A0 (en) 2002-02-10
WO2000008043A2 (fr) 2000-02-17
CN1321165A (zh) 2001-11-07
BR9912732A (pt) 2001-11-27
JP2002522448A (ja) 2002-07-23
CA2338983A1 (fr) 2000-02-17

Similar Documents

Publication Publication Date Title
US12606596B2 (en) Self-assembling insect ferritin nanoparticles
AP1282A (en) HIV envelope polypeptides and vaccine.
JP3967374B2 (ja) 同調的インビボ遺伝子発現
US7939083B2 (en) Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
KR100547049B1 (ko) 바이러스 감염증 치료를 위한 조성물 및 방법
EP1102788A2 (fr) Prevention et traitement de pathologie virale
JP2000505299A (ja) 合成ｈｉｖ遺伝子
JP2000516445A (ja) 合成遺伝子を含むワクチン
NL8701950A (nl) Monoclonale antilichamen en peptiden, geschikt voor de behandeling en diagnose van hiv infecties.
JP2005503147A (ja) ウイルスコートタンパク質／受容体キメラおよび使用方法
US6585979B1 (en) HIV envelope polypeptides and immunogenic composition
JP2009511623A (ja) レンチウイルスベクターベースのワクチン
JPH05506647A (ja) Ｈｉｖ逆転写酵素に対する細胞毒性ｔ細胞免疫を刺激するペプチド
Hunter et al. Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine
WO1998041536A1 (fr) Glycoproteines enveloppes de vih et vis a glycosylation deficiente
WO1998041536A9 (fr) Glycoproteines enveloppes de vih et vis a glycosylation deficiente
JP2003520786A (ja) コドン最適化ｈｉｖ−１ｐｏｌおよび修飾ｈｉｖ−１ｐｏｌを発現するポリヌクレオチドワクチン
JP2004121266A (ja) コンビナトリアルポリペプチド抗原
JP2004525604A (ja) Ｈｉｖアクセサリータンパク質をコードするｄｎａワクチン
CN118765283A (zh) 通用沙贝病毒疫苗
MXPA01001264A (en) Prevention and treatment of viral disease
US7537769B2 (en) Webbed immunogens comprising recombinant human immunodeficiency virus (HIV) envelope glycoproteins and the M9 scorpion toxin
EP1359221B1 (fr) Protéines antisens d' VIH
Peet Towards an epitope specific vaccine: Murine immune responses to wildtype and mutant HIV-1 gp120
AU2004201321A1 (en) Compositions and methods for treating viral infections

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99811641.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2338983

Country of ref document: CA

Ref document number: 2338983

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 141211

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001264

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017001483

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 57715/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999945011

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999945011

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017001483

Country of ref document: KR

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-92, DESCRIPTION, REPLACED BY NEW PAGES 1-92; PAGES 93-104, CLAIMS, REPLACED BY NEW PAGES 93-104; PAGES 1/12-12/12, DRAWINGS, REPLACED BY NEW PAGES 1/23-23/23; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 1999945011

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020017001483

Country of ref document: KR